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The research undertaken for this MPH dissertation compares the accuracy of handheld 
echocardiography for the detection of rheumatic heart disease to the reference standard 
using systematic review methods. 
 
PART A is a research protocol which describes the background and process of the proposed 
review. This section details the quantitative methods to be used in the systematic review 
and meta-analysis of studies which assess the diagnostic accuracy of handheld 
echocardiography for rheumatic heart disease detection in children and adolescents. The 
proposed systematic review methods are based on those of the Cochrane Collaboration.  
 
PART B is an extended literature review which expands on some of the topics raised in the 
background section of the protocol. A more in depth insight into the context surrounding 
the proposed research is offered and its importance highlighted. By reviewing the current 
body of evidence, this literature review aimed to both describe and contextualise the global 
burden of rheumatic heart disease whilst providing a rationale for further research into 
better screening modalities. Similarly, it also sought to describe the importance of 
understanding rheumatic heart disease epidemiology so that future research and screening 
programmes may be targeted accordingly.  
 
PART C is a full systematic review of diagnostic test accuracy studies presented as a journal 
‘ready’ manuscript in a format suitable for submission to PLoS ONE. The background to the 
systematic review is briefly summarised after which the results are then presented and 
discussed. The main findings, from seven included studies, provide some evidence for the 
potential of handheld echocardiography to increase access to echocardiographic screening 
for rheumatic heart disease. Lastly and in conclusion, implications arising from the findings 
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ABBREVIATIONS AND DEFINITIONS 
 
Abbreviations 
ARF Acute Rheumatic Fever 
AR Aortic Regurgitation 
AV Aortic Valve 
CVD Cardiovascular Disease 
DALYs Disability Adjusted Life Years 
ECG Electrocardiogram 
GAS Group A Streptococcus 
HAND Handheld Echocardiography 
HCU Hand Carried Ultrasound 
HHCU Hand-Held Cardiac Ultrasound 
LMICs Low and Middle Income Countries 
MR Mitral Regurgitation 
MS Mitral Stenosis 
MV Mitral Valve 
RHD Rheumatic Heart Disease 
STAND Standard Echocardiography 
WHF World Heart Federation 











Asymptomatic A health condition which does not display any clinical signs or symptoms. 
Aetiology The cause or set of causes or manner of causation of a disease or condition. 
Endemic 
Usual pervasiveness of a disease or condition among certain populations or within a 
geographic area.[1] 
Epidemiology Burden (incidence/prevalence), distribution and possible control of diseases. 
Morphology The structure and form of a specific organ, tissue, organism or cell. 
Pathogenesis The manner of origination and development of a disease. 
Pathological 
Altered or caused by disease (i.e. pathological changes in the body) / indicative of 
disease (i.e. pathological symptoms). 
Pathophysiology 
The disordered processes associated with disease or injury / the functional changes 
that accompany a particular disease. 
Physiological 
Relating to physiology / characteristic of or appropriate to an organism’s healthy or 
normal functioning / differing in, involving or affecting physiological factors. 
Regurgitation The abnormal backward flowing of blood through a heart valve. 
Sequelae A condition that is the result of a preceding disease or injury. 
Stenosis The narrowing or constriction of an opening such as a heart valve. 
Symptomatic A health condition which displays clinical signs or symptoms. 
Valve 
An opening between two chambers of the heart or between a chamber of the heart 










Rheumatic heart disease (RHD) is a permanent heart valve condition resulting from an 
abnormal immune reaction to group A streptococcal infection typically occurring in 
childhood.[2] If left untreated, disease progression can result in irreversible heart valve 
damage, cardiac failure, stroke and premature death.[3,4] Significantly, RHD is a 
preventable and treatable chronic condition which mostly affects disadvantaged 
populations across the world.[3] Even though the disease has mostly been eradicated in 
North America and Europe, barring a few indigent pockets, it remains prolific in areas of the 
Middle East, the South Pacific, Africa as well as Central and South Asia.[3] 
The continued persistence of RHD contributes to considerable amounts of preventable 
morbidity and mortality, particularly among adolescents and young adults.[5] This adds 
additional strain to what are often already overburdened health systems, with endemic 
regions, which are typically poorly resourced, bearing the brunt of the disease.[2,6] 
Furthermore the accurate detection of subclinical RHD in children and adolescents remains 
hampered by the cost of diagnostic machinery and scarcity of trained personnel.[7]  
Echocardiography has been demonstrated to significantly enhance screening programmes 
for the detection of RHD over auscultation alone.[5,8] However, the cost of standard 
portable echocardiographic machines is prohibitive in many RHD-endemic areas and the 
training and expertise required to conduct a full-screening echocardiogram according to the 
2012 World Heart Federation (WHF) criteria restricts its wide scale use.[5,9] Alternative RHD 
screening tests, which are both accurate and affordable, are therefore needed in many 
endemic areas.  
 





Recently, handheld echocardiography has become widely available with a variety of clinical 
uses.[10] Similarly, diagnostic accuracy has already been demonstrated in a number of 
studies assessing its value as a screening tool, despite some limitations such as lack of 
Doppler capabilities.[7] Due to the non-invasive, safe, portable and relatively inexpensive 
nature of handheld echocardiography, the device has been presented in recent publications 
as a promising alternative to standard echocardiography in resource-limited and remote 
settings.[8–11] 
1.1 Rationale 
Incorporating handheld echocardiography into screening programmes could provide the 
potential for significantly more cases of subclinical RHD to be detected, thereby reducing 
the time to commencement of secondary prophylaxis and thus, in turn, improving long term 
outcomes.[13] However, in order to test the assertion that HAND could provide a promising 
alternative to STAND in endemic areas, the diagnostic accuracy of handheld 
echocardiography needs to be evaluated using a systematic approach. This review, 
therefore, proposes to evaluate the accuracy of handheld echocardiography for the 
detection of RHD in children and adolescents within a screening setting. 
We anticipate the findings of this review will generate new quantitative evidence whilst also 
highlighting any critical gaps in research. It is envisaged that this review will assist clinicians 
by prompting guideline developers to establish new evidence-based guidelines for 
diagnosing RHD with handheld echocardiography. Ultimately, this will improve the 
management of patients with RHD, as effective treatment of subclinical RHD requires 
accurate and timely diagnosis. 





2.1 Primary Objective 
To identify, evaluate and synthesise existing literature reporting on the diagnostic accuracy 
of handheld echocardiography compared to standard echocardiography (2D, continuous-
wave, and colour-Doppler echocardiography) performed by an experienced imager in 
conjunction with the 2012 WHF criteria for the detection of any RHD in children and 
adolescents.  
2.2 Secondary Objective 
To investigate potential sources of variation in relation to age, gender, geographical 
location, echocardiographic criteria and echocardiographer expertise in detecting subclinical 
RHD with handheld echocardiography.  
3. REVIEW QUESTION 
What is the accuracy of handheld echocardiography for the detection of RHD in children and 
adolescents worldwide? 
4. METHODS 
The protocol was prepared according to the Preferred Reporting Items for Systematic 
review and Meta-Analysis (PRISMA) guidelines.[14] 
4.1 Study Selection Criteria 
4.1.1 Types of studies 
We will include all primary observational studies which compare the diagnostic accuracy of 
handheld echocardiography to the reference standard; standard echocardiography 




performed by an experienced imager and in conjunction with the 2012 WHF criteria. Eligible 
studies can be of a cross-sectional, cohort or diagnostic case-control design, provided both 
cases and controls have been sampled from the same population. Descriptive studies such 
as case studies/series will be excluded from this review. 
4.1.2 Types of participants 
We will consider all studies in which samples of study participants are either, a randomly, or 
consecutively selected series of individuals from populations in which RHD is prevalent 
worldwide for inclusion. For the purposes of this review, children and adolescents will be 
defined as being between the ages of 5 and 17 years. More specifically, participants will be 
considered children if they are between 5 and 9 years of age and adolescents if they are 
between 10 and 17 years of age. 
4.1.3 Types of diagnostic methods 
We will include studies evaluating the accuracy of handheld echocardiography for RHD 
detection. There will be no restrictions regarding the type of handheld device used or the 
aptitude of person performing the cardiac ultrasound, however these data will be recorded 
and analysed accordingly. Studies will be deemed eligible for inclusion if the reference 
standard constituted the interpretation of echocardiographic findings using the 2012 WHF 
criteria when echocardiographic assessment by 2D, continuous-wave, and colour-Doppler 
echocardiography was performed by a cardiologist or cardiac sonographer.  
We will exclude all studies published before 2012 in order to omit any study which does not 
use standard echocardiography in conjunction with the 2012 WHF criteria as the reference 
standard. We will consider all studies which evaluate any RHD (definite and borderline) as 
the condition of interest for inclusion in this review. All case definitions will be consistent 
with the 2012 WHF criteria.[15]  





4.1.4 Types of outcome measures 
Studies which report on, or contain the data necessary to extract information on the 
proportions of true positives (TP), false positives (FP), true negatives (TN) and false 
negatives (FN) will be included. Studies which enrolled only those with a confirmed RHD 
diagnosis will be excluded on account of the potential for overestimation of sensitivity. 
Studies in which we are unable to generate two-by-two tables, as well as different studies 
which report on duplicate data will not be considered for inclusion in this review. In 
instances where studies report on the same data, the most recent and complete version will 
be used. 
 







Primary observational studies (cross-sectional, cohort 
or diagnostic case-control) evaluating the diagnostic 
accuracy of handheld echocardiography 
Descriptive studies such as case studies 
and case series. 
Study Participants 
Children and adolescents between the ages of 5 and 17 
years from RHD prevalent populations worldwide.  
Participants with a confirmed RHD 
diagnosis.  
Target Condition 
Borderline or definite RHD consistent with case 
definitions as defined by the 2012 WHF criteria. 
Case definitions which are not 
consistent with the 2012 WHF criteria. 
Index Test 




Standard echocardiography (2D, continuous-wave, and 
colour-Doppler echocardiography) performed and 
interpreted by an expert cardiologist or cardiac 
sonographer and in conjunction with the 2012 WHF 
criteria.  
Diagnostic criteria other than the 2012 
WHF criteria. 
Outcome Measures 
Proportions of true positives (TP), false positives (FP), 
false negatives (FN) and true negatives (TN).  
Insufficient data to generate 2x2 tables.  
Studies reporting on the same data. 
 
 





4.2 Search Methods  
4.2.1 Electronic searches 
A comprehensive electronic literature search of PubMed, Scopus, Web of Science and 
EBSCOhost will be conducted to identify relevant literature. No restrictions in terms of 
language will be applied during the search. Searches will however be limited to only include 
articles published from 2012 up until the present as a proxy for studies conducted from 
2012 onwards. All sources will be systematically searched using a combination, where 
relevant, of both free text words and Medical Subject Heading (MeSH) terms. Search 
strategies will be tailored to meet the requirements of each electronic database as in table 2 
below. Search terms will include synonyms for 'rheumatic heart disease', 'echocardiography' 
and ‘handheld’. A list of all articles identified through the literature search will be compiled 
and references managed using Mendeley software.  
4.2.2 Additional searches 
In addition, a manual search of all eligible articles' reference lists, articles citing eligible 
articles as well as relevant review articles will be carried out in order to identify any 
additional literature not identified by the comprehensive electronic literature search. 
Abstracts from any relevant conference proceedings will also be searched for among 
appropriate websites and followed up on if eligibility requirements are sufficiently met. 
Finally, experts in the field will be contacted for additional information if necessary.  




Table 2. Search strategy 
Database Search Terms Limits 
PubMed  
 
((((((((((((((((Hand-held) OR handheld) OR hand held) OR hand-carried) OR hand carried) OR HAND) OR HCU) OR 
HHCU) OR pocket size) OR pocket sized) OR portable) OR miniaturization) OR miniaturized) OR focused) OR focus)) 
AND (((("Echocardiography"[Mesh]) OR echocardiography) OR echocardiographic) OR cardiac ultrasound)) AND 
((("Rheumatic Heart Disease"[Mesh]) OR rheumatic heart disease) OR RHD) 




1. Hand-held OR handheld OR hand held OR hand-carried OR hand carried OR HAND OR HCU OR HHCU OR pocket 
size* OR portable OR miniatur* OR focus* 
2. Echocardiograph* OR cardiac ultrasound  
3. Rheumatic Heart Disease OR RHD  
#1 AND #2 AND #3 
Limited to 
2012-2017 
ISI Web of Science  
1. Hand-held OR handheld OR hand held OR hand-carried OR hand carried OR HAND OR HCU OR HHCU OR pocket size 
OR pocket sized OR portable OR Miniaturization OR Miniaturized OR focused OR focus  
2. Echocardiography OR Echocardiographic OR cardiac ultrasound  
3. Rheumatic Heart Disease OR RHD  






S1. Hand-held OR handheld OR hand held OR hand-carried OR hand carried OR HAND OR HCU OR HHCU OR pocket 
size OR pocket sized OR portable OR Miniaturization OR Miniaturized OR focused OR focus  
S2. Echocardiography OR Echocardiographic OR cardiac ultrasound  
S3. Rheumatic Heart Disease OR RHD  
S1 AND S2 AND S3 
Limited to 
2012-2017 




4.3 Selection of Studies for Inclusion 
The titles and/or abstracts of all articles identified by the literature search will be screened 
independently by two reviewers (LT and LA). Based on the predefined inclusion and 
exclusion criteria any clearly ineligible studies will be excluded. Following this, LT and LA will 
then review the full text versions of all potentially eligible studies in order to assess their 
eligibility. Any discrepancies regarding eligibility will be resolved through discussion and 
consensus with a third reviewer (ME).  
5. DATA EXTRACTION AND MANAGEMENT 
Using a predefined data extraction form, LT and LA will independently extract the following 
information from all studies meeting the criteria for inclusion; 
 Study identifiers: Author(s), year of publication, journal 
 Study characteristics: Study design, study country/setting/context, study 
population/participants, sample size, participant recruitment procedures, participant 
demographics and RHD prevalence (pre-test probability)  
 Reference standard and index test details;  
º General: test positive or negative 
º Specific: individual findings on cardiac ultrasound 
º Expertise of person(s) performing and/or interpreting tests: expert vs non-
expert  
º Diagnostic criteria: test threshold(s) 
º Number of missing or unavailable test results 
 Diagnostic test outcome measures: Sensitivity, specificity, positive and negative 
predictive values, number of TP, FP, TN and FN 
 




If necessary any disagreements will be resolved through discussion with a third reviewer 
(ME) until a consensus is reached. Any data missing from the reports of included studies will 
be requested from study authors by LT. In cases where studies have used different 
diagnostic criteria for handheld echocardiography, attempts will be made to standardise 
them to mirror the 2012 WHF criteria as closely as possible. The information garnered 
through the data extraction process will be used to determine each study’s quality as well as 
for synthesising evidence. 
6. RISK OF BIAS AND QUALITY ASSESSMENT  
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool (see table 3) will be 
used to assess the risk of bias and concerns regarding applicability of all included 
studies.[16] The tool encompasses four domains which have been tailored to meet the 
specific requirements of the review. Two reviewers will independently assess the risk of bias 
in all included studies according to the revised QUADAS-2 criteria. Any discrepancies will be 
resolved through discussion until consensus is reached and with the assistance of a third 
reviewer if necessary. Both text and graphics will be used to demonstrate the results.          




Table 3. Design-specific QUADAS-2 criteria to assess methodological quality 
CATEGORIES 
DOMAINS 




Briefly describe the methods of patient 
selection: 
Describe the IT (HAND), how it was 
conducted and interpreted: 
Describe the RS (STAND) how it was 
conducted and interpreted: 
Describe patients that did not receive 
HAND, &/or STAND or who were 
excluded from the 2X2 table: 
Describe the time interval & any 
interventions between the HAND & 
STAND: 
Indicator Questions  
(yes, no, unclear) 
Was a consecutive or random sample of 
patients enrolled? 
Were the HAND results interpreted 
without knowledge of the results of 
STAND? 
Was STAND likely to correctly classify 
the target condition? 
Was there an appropriate time interval 
between HAND & STAND? 
Was a case-control design avoided? 
Was a pre-specified threshold used? 
Were the STAND results interpreted 
without knowledge of the HAND 
results? 
Did all patients receive STAND & was it 
the same RS? 
Did the study avoid inappropriate exclusions? 
Were all patients included in the 
analysis? 
*Risk of Bias 
(low, high, unclear) 
Based on the indicator questions, could the 
selection of patients have introduced bias? 
Based on the indicator questions, could 
the conduct or interpretation of HAND 
have introduced bias?  
Based on the indicator questions, could 
STAND, its conduct, or its 
interpretation have introduced bias? 
Based on the indicator questions, could 
the patient flow and timing have 
introduced bias?  
Concerns Regarding 
Applicability  
(low, high, unclear) 
Describe included patients (prior testing, 
presentation, intended use of HAND and 
setting): 
Based on the description of included patients, 
are there concerns that the included patients 
do not match the review question? 
Are there concerns that HAND, its 
conduct, or interpretation differ from 
the review question? 
Are there concerns that the target 
condition as defined by STAND does 





* Criteria for Grading Risk of Bias: 
 If all indicator questions for a single domain are answered “yes” then the risk of bias will be judged as being “low” 
 If any indicator question is answered “no” then the potential for bias will be flagged and the review authors will be required to judge the risk of bias with the assistance of the senior author (ME) 
 If all or most indicator questions were answered "no" then the risk of bias will be judged as being "high" 
 Indicator questions are can only be answered as “unclear” when the data are insufficient to allow for the formulation of a judgment 
**Adapted from Whiting et al.[16] 




7. DATA ANALYSIS AND SYNTHESIS 
7.1 Subgroup and Sensitivity Analyses 
7.1.1 Subgroup analysis 
Subgroup analysis may be performed, considering specific characteristics of the studies, 
such as echocardiography protocol, training background of the examiner, age and 
geographical location. 
7.1.2 Sensitivity analysis 
We will conduct a sensitivity analysis to investigate the effect of variations in criteria on the 
overall accuracy of diagnosis. In addition we will explore the effect of excluding studies with 
a high risk of bias on the accuracy of summary estimates, sensitivity and specificity. We will 
not investigate publication bias. 
7.2 Statistical Analysis and Data Synthesis 
7.2.1 Statistical analysis 
We will first analyse data descriptively by plotting the sensitivity and specificity (including 
95% confidence intervals) of all included studies in both forest plots and Receiver Operating 
Characteristic (ROC) space. These plots will be generated using the Review Manager 
software package.[17] 
7.2.2 Data synthesis 
If there are sufficient data, we will conduct a meta-analysis to produce summary results of 
sensitivity and specificity. Because we anticipate that studies will have different positivity 




thresholds due to the use of different sets of diagnostic criteria, we will pool the results 
using the Hierarchical Summary Receiver Operating Characteristic (HSROC) method. 
Meta-analysis will be performed using SAS/STAT® software.[18]  We will also explore, 
through meta-regression, the relationship of test accuracy with categorical or continuous 
covariates such as test threshold.[19] 
7.2.3 Assessment of heterogeneity 
Investigations of heterogeneity will initially begin by visually examining the forest and ROC 
plots for heterogeneity in sensitivity and specificity. We will then analyse the possible 
sources of heterogeneity as covariates in the statistical models. Potential sources of 
heterogeneity to be investigated as categorical variables include; age (children vs 
adolescents), sex (male vs female), geographical location (high vs low and middle income 
countries), diagnostic criteria (single vs multiple views and different thresholds) and 
echocardiographer expertise (expert vs non-expert). 
7.3 Presenting and Reporting of Results 
The study selection process will be summarised in the form of a flow diagram detailing the 
reasoning behind all exclusions. Results will be reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[20] 
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10. DISSEMINATION 
The planned review will provide a summary of the diagnostic accuracy of handheld 
echocardiography. Results may feed into evidence-based guidelines and will therefore be 
disseminated to members of the WHF criteria working group. Should the findings of this 
review warrant a change in clinical practice, a summary report will be circulated amongst 
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This literature review examines the current state of knowledge on rheumatic heart disease 
(RHD) epidemiology, aetiology, pathogenesis, diagnosis and screening. Through an 
evaluation of the existing body of evidence, this literature review will both describe and 
contextualise the global burden and distribution of RHD in relation to the history and 
development of various diagnostic and screening modalities. A synthesis and summary of 
relevant literature provides context and rationale for the succeeding systematic review. 
1.2 Methods 
An exploratory approach involving iterative methods was employed for the collection and 
synthesis of relevant evidence. The most recent and seminal works on RHD were first 
searched for in PubMed and Google Scholar using a broad search strategy which included a 
variety of search terms for RHD, epidemiology, screening and diagnosis. Thereafter, further 
pertinent literature was identified through hand searching the bibliographies of initially 
identified works as well as by following up on articles cited by relevant sources. 
The scope of this literature review is broad and begins with a brief history of RHD in order to 
situate current global agendas. Thereafter, the epidemiology of RHD is outlined and the 
aetiology and pathogenesis of the disease is summarised. A précis of the history and 
development of diagnostic modalities then follows providing context for the concluding 
discussion on the current importance and possible future role of echocardiographic 
screening for RHD. 
 




2.1 Historical Context 
RHD has largely been eradicated in North America and Europe, barring a few indigent 
pockets within some developed countries. [1] This trend can mainly be attributed to 
improvements in living circumstances, access to health care and the use and availability of 
high-quality penicillin.[1,2] Yet while the incidence and prevalence of both acute rheumatic 
fever (ARF) and RHD has been steadily decreasing in developed countries since the early 
1990s, rates continue to remain constant or increase in many developing countries.[3] 
Contributing to considerable amounts of preventable morbidity and mortality, particularly 
among adolescents and young adults, the disease adds additional strain to what are often 
already overburdened health systems.[4–6] What’s more, endemic regions are typically 
poorly resourced and often lack the capability to treat advanced RHD which requires 
expensive surgical procedures.[1] 
2.2 Current Global Agenda 
An unfortunate result of the declining rates of ARF and RHD in developed countries was a 
corresponding drop in associated research.[7] Additionally, while the pathogenesis of the 
condition is indeed better understood now, advances in the treatment and management of 
the disease have largely revolved around what are often inaccessible and expensive 
solutions for advanced RHD.[8] Recently, a resurgence in ARF/RHD awareness within global 
health contexts has occurred as recognition of the disease’s continued persistence in many 
low and middle-income countries (LMICs) has grown.[7,9] 
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RHD is increasingly receiving more prominence in global agendas where advocacy for its 
eradication has been spearheaded by organisations such as the World Heart Federation 
(WHF), who in 2012 set the ambitious goal of achieving “25 x 25 < 25”.[10,11] This goal 
seeks to see a 25% reduction in premature deaths resulting from RHD in those younger than 
25 years of age by the year 2025.[4,8]  With efforts such as those espoused by the 2017 
WHF roadmap for improved RHD prevention and control, the actualisation of this goal has 
become a real possibility.[13] 
Likewise, numerous calls to action emphasising research priorities and agendas have been 
publicised in recent years.[14–19] On June 1st, 2017 these calls were finally answered when 
the World Health Organisation (WHO) announced that a resolution to eradicate ARF and 
RHD will be presented for adoption at the World Health Assembly in 2018. This will mark the 
first time in recent history where RHD has been recognised as a global health priority at this 
level and will institute a worldwide commitment to the prioritisation of ARF and RHD 
prevention, management and control strategies in endemic areas.[20] 
3. EPIDEMIOLOGY 
Establishing the real burden of RHD and understanding the distribution of ARF/RHD both 
between and within populations is crucial for the formulation and effective implementation 
of preventive, diagnostic and management programmes.[2] 
3.1 Global Burden 
3.1.1 Acute rheumatic fever 
Up until 100 years ago, ARF was second only to tuberculosis as the leading cause of death 
among young adults in the United States and the principal cause of mortality among 
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American school-children.[7] Likely due to improvements in hygiene, living conditions and 
sanitation,[7] the annual incidence of ARF in the United States decreased to around 4-6 
cases per 100 000 children during the latter half of the 1900s.[21] The same cannot be said 
of many LMICs where a vastly dissimilar pattern mirroring that of the early developed world 
still exists.[22] 
A 2005 report commissioned by the WHO analysed population-based data on ARF and RHD 
spanning 20 years and found that 471, 000 cases of ARF occur annually worldwide,[4] with 
approximately 60% of those living in endemic areas going on to develop RHD.[23] The same 
report also found that the number of new cases in children between 5 and 15 years of age 
ranged from 10 cases per 100, 000 in developed countries, to 374 cases per 100, 000 in the 
Pacific area.[4] These figures highlight the discrepancies in disease burden between the 
developed world and LMICs. 
3.1.2 Rheumatic heart disease 
Findings from the 2015 Global Burden of Disease study showed that the worldwide estimate 
for RHD prevalence has risen to nearly 34 million cases,[24] while an estimated 80 million 
people might also be living with subclinical RHD.[7] Furthermore, it was reported that as 
many as 319, 400 premature deaths were attributable to the disease in 2015.[25] Although, 
these estimates are likely to be an underestimate due to the widespread scarcity of good 
quality epidemiologic data on the disease, particularly from developing countries.[4,26] 
The prevalence of RHD progressively increases as age increases,[27] with the disease 
peaking in adults aged between 25 and 34 years of age.[26] Significantly, RHD remains the 
most commonly occurring acquired cardiovascular disease (CVD) among people under the 
age of 25, thereby affecting those afflicted during their most productive years.[28] 
PART B: Literature Review Lisa Helen Telford February 2018 
5 
 
A recent systematic review of the burden of RHD among children and adolescents in 
endemic areas calculated the pooled prevalence of clinical RHD to be 2.7 per 1000 people 
(95% CI: 1.6 – 4.4). In comparison the pooled prevalence of subclinical RHD was estimated at 
21.1 per 1000 people (95% CI: 14.1 – 31.4), which the author’s note is around seven to eight 
times greater than that of clinically manifest RHD.[27] 
Differentiating between clinical and subclinical disease is therefore particularly important as 
it would appear that a much larger proportion of all RHD cases are subclinical. However, 
where clinical or definite RHD, defined as “structural and functional changes on 
echocardiography consistent with RHD in the presence of a pathological murmur”[29] is 
relatively easy to detect and diagnose, a diagnosis of subclinical or borderline RHD defined 
as “RHD detected on echocardiography without an associated clinically pathological 
murmur”[30] is more challenging and can be unreliable due to the subjectivity involved in 
assessing some morphological features.[31] 
3.2 Global Distribution 
3.2.1 Between populations 
The burden of RHD is disproportionally distributed both within and between countries with 
the global poor bearing the brunt of disease as can be seen in the figure below.[11,32] 
According to 2013 estimates, the disease remains prolific in areas within Africa, the Middle 
East, the South Pacific, as well as Central and South Asia.[12,28] Notably, while the global 
North has experienced a significant decrease in the prevalence of RHD since 1990, parts of 
Africa, the Middle East, Central and South America as well as the Pacific region have seen 
increases in disease rates of up to 20% or more. 























Figure 1. Global burden of rheumatic heart disease by country based on 2013 estimates (source: Carapetis et al., 2016) [32] 
3.2.2 Within populations 
Whilst the occurrence of ARF is similar in both males and females, the risk of developing 
RHD is 1.6 to 2 times greater in women compared to men.[32] Although a number of 
reasons for this trend have been hypothesised, the exact cause remains unclear. Suggested 
explanations include the possibility of innate susceptibility, hormonal factors, limited access 
to preventive medical services, greater exposure to the bacterial pathogen; streptococcus 
pyogenes and the worsening of existing subclinical RHD in pregnancy, oftentimes leading to 
initial diagnosis.[23,26] 
Additionally while an association with ethnic origin has yet to be established, there is some 
evidence that points to an underlying proportion of between 3 and 6% of any population 
being genetically susceptible to ARF.[26] In essence, both the burden and distribution of ARF 
and RHD are determined by a multitude of often intersecting environmental, social, 
behavioural and biological factors.[21] 




Risk factors associated with the development of ARF and the subsequent outcome RHD are 
both numerous and varied, with environmental factors being arguably the most significant 
determinants of disease distribution.[33] Associated risk factors can be broadly categorised 
as being biological, behavioural or environmental in nature. 
4.1 Biological Risk Factors 
Broadly speaking, biological risk factors for the development of RHD include genetic 
predisposition, older age, being female and a history of ARF.[26] 
4.2 Behavioural Risk Factors 
Behavioural factors associated with increased risk of developing RHD include poor 
adherence to treatment, lack of secondary prophylaxis and limited knowledge about the 
condition.[26] Importantly insufficient awareness and knowledge regarding the symptoms, 
treatment and consequences of streptococcal pharyngitis within communities has major 
implications for the expression of ARF and RHD within populations.[33] 
4.3 Environmental Risk Factors 
The indirect yet imperative role that both environmental and socio-economic factors play in 
determining the amount and severity of ARF and RHD within populations has been well 
established.[33] Socio-environmental risk factors associated with the aetiology of RHD 
include low socio-economic status (SES), substandard living conditions, overcrowding, 
shortage of resources for health care, insufficient access to medical care and inadequately 
trained health care providers.[33] Consequently a combination of biological, behavioural 
and environmental risk factors will result in the pathogenic development of RHD. 




5.1 Pathogenic Pathway 
The pathogenesis of RHD (see figure 2) is a complex process involving genetic as well as 
other factors.[34] While the molecular pathways between GAS infection and ARF remain 
insufficiently understood, it has been definitively established that ARF is caused by an 
































Figure 2. An illustrated pathogenic pathway of ARF and RHD (source: Carapetis et al., 2005) [26] 
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In essence the pathogenic pathway of RHD begins with the recurrence of streptococcal 
infections in predisposed hosts. If left untreated the onset of ARF then follows which 
inevitably leads to the development of RHD if insufficient secondary preventive measures 
are taken.[1] Consequently, RHD most often occurs as a result of the cumulative damaging 
effects of repeated ARF episodes, although an initial episode can also lead directly to 
RHD.[26] 
Chronic RHD is a disease characterised by progressive and irreversible valvular lesions.[34] 
Heart valve damage resulting from RHD can lead to congestive heart failure, pulmonary 
hypertension, endocarditis, stroke, atrial fibrillation and premature death.[3,35,36] While 
there are a number of clinical signs and symptoms indicating manifest disease at each stage 
along the pathogenic pathway, patients may remain largely asymptomatic or else be 
unaware of their symptoms until the advanced stages.[35] 
6. CLINICAL MANIFESTATION 
6.1 Signs and Symptoms 
Clinical signs and symptoms due to GAS infections as well as their non-suppurative sequelae 
have been well documented over the years (see table 1 below). ARF presents with one or 
more of a constellation of symptoms called the “Jones Criteria” while symptomatic RHD is 










Significantly, asymptomatic cases are not uncommon and misdiagnosis or failure to detect 
both pharyngitis and ARF often occurs.[29] This is evidenced by the fact that approximately 
40% of all individuals presenting with established RHD cannot recall a recognisable episode 
of ARF.[29,35] 
7. DIAGNOSIS 
A variety of different methods, each with their own advantages and disadvantages, are 
employed by physicians for the detection and definitive diagnosis of RHD. Typically a 
combination of various techniques will yield a confirmed diagnosis by an experienced 
cardiologist, with the current gold standard test being a clinical examination in conjunction 
with a detailed echocardiographic assessment.[29] In those without a clear history of ARF, a 
diagnosis is made in one of two ways; either as a result of a confirmatory diagnosis following 
a positive screening test or if cardiac symptoms are present usually indicating advanced 
disease.[29] It should be noted that a diagnosis made in absence of a confirmed preceding 
ARF episode can be uncertain.[29] 
 
 
Table 1.  Main clinical signs and symptoms of GAS, ARF and RHD* [38] 
Condition Signs and/or symptoms 
Pharyngitis Sore throat, fever, malaise 
Acute Rheumatic Fever  Polyarthritis, carditis, rapid and jerky movements, rash, subcutaneous nodules 
Rheumatic Heart Disease 
Mitral and/or aortic regurgitation with potential stenosis over time presenting 
as: cardiac murmur, angina, syncope, fatigue, exertional dyspnoea 
*Adapted from Walker et al., 2014: p.266 
Abbreviations: GAS, Group A Streptococcus; ARF, Acute Rheumatic Fever; RHD, Rheumatic Heart Disease 
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7.1 Diagnostic Tests 
7.1.1 Cardiac auscultation 
Cardiac auscultation for the detection of RHD refers to the action of listening to the heart 
sounds with a stethoscope in order to detect a heart murmur in patients with or without a 
history of ARF prior to echocardiographic confirmation.[30,39] Up until recently, this 
method has been the only non-invasive diagnostic device available to physicians in remote 
and resource-limited settings.[30] Whilst cardiac auscultation is undoubtedly a simple, cost 
effective and accessible tool it remains inherently subjective and a progressively challenging 
clinical skill to master.[40] 
7.1.2 Cardiac ultrasound 
Cardiac ultrasound has been credited as being the most significant development in 
diagnostic cardiology since the invention of X-Rays.[41] The first echocardiograms of the 
heart using reflected sound waves were produced in 1953 by Drs Inge Elder and Helmuth 
Hertz, [41,42] who detailed its value for evaluating mitral-valve disease.[43] The use of M-
mode echocardiography (echo) for assessing left-ventricular dimensions in clinical practice 
was then standardised by Dr Harvey Feigenbaum during the 1960s.[43] Subsequently, the 
1970s saw the advent of two-dimensional (2D) and pulsed Doppler echocardiography 
followed by colour Doppler in the 1980s.[43] As a result new methods for routine bedside 
assessment of cardiac structure and hemodynamics came into being.[43] 
7.1.3 Standard echocardiography 
Standard echocardiography (2D, continuous-wave, and colour-Doppler echocardiography)  
or STAND is a highly sensitive and specific method used to screen for the presence of RHD in 
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suspected cases.[5,23] It is widely accepted as the best non-invasive reference or gold 
standard test currently available for the detection of RHD when performed by a trained 
cardiologist.[5] 
Echocardiography allows clinicians to rapidly obtain vital information about the size, 
structure and function of the heart through the application of its high frequency ultrasound 
capabilities whilst colour-Doppler is used to assess hemodynamics.[44,45] In the context of 
RHD, echocardiographic assessment permits the grading of regurgitation severity through a 
combination of techniques which make use of the machine’s 2D and colour-flow imaging 
abilities.[23] Furthermore, echocardiographic images can be evaluated immediately thereby 
enabling speedy diagnosis within an array of different settings.[44] 
To date no studies comparing echocardiographic with post-mortem findings exist. Similarly, 
there is currently no alternative gold standard test for the detection of RHD. This makes the 
estimation of the machine’s inherent diagnostic accuracy challenging. Moreover, whilst the 
technical competency of this diagnostic modality is impressive,  its accuracy is entirely 
reliant on the proficiency of the person(s) performing, analysing and interpreting 
images.[44] This has led researchers to adopt an evolving consensus which assumes 
sensitivity on echo to be between 95 and 100% with specificity varying in range 
accordingly.[46] 
Nevertheless, since its introduction into clinical practice during the 1970s, [45] 
echocardiography has been shown to have the ability to detect significantly more cases of 
early RHD compared to clinical examination alone [36] with reports indicating moderate to 
excellent inter-observer agreement.[48,49] 
PART B: Literature Review Lisa Helen Telford February 2018 
13 
 
7.2 Diagnostic Criteria 
In 2009 under the patronage of the WHF, a number of experts in echocardiographic 
screening for RHD from across the world assembled to form an international advisory 
board.[50] Together these 21 experts developed evidence-based guidelines for the 
echocardiographic detection of RHD.[30] The guidelines were specifically developed with 
the intention of defining the minimum echocardiographic criteria for RHD diagnosis in 
asymptomatic patients without a clear history of ARF.[30,50] Officially released in 2012, the 
diagnostic guidelines were formulated for use in clinical practice as well as in screening 
programs. Soon thereafter they became accepted as the gold standard for screening on 
echo.[50] 
The 2012 WHF criteria for the echocardiographic diagnosis of RHD [30] (see table 2 below) 
require assessment using 2D, continuous-wave and colour Doppler echocardiography. 
Valvular features identified by echocardiography assigns individuals into one of three main 
categories; ‘normal’, ‘borderline RHD’ or ‘definite RHD’. Specific findings are then used to 
further classify individuals according to subcategories of which there are three under 
‘borderline RHD’ and four under ‘definite RHD’.[30] The 2012 report also stressed that 
results from echocardiographic screening should always be interpreted together with the 
patient’s clinical findings and history as well as in conjunction with their pre-test probability 




PART B: Literature Review Lisa Helen Telford February 2018 
14 
 
Table 2. 2012 WHF criteria for echocardiographic diagnosis of RHD [30] 
Echocardiographic criteria for individuals aged ≤ 20 years 
1. Definite RHD (either A, B, C or D): 
A) Pathological MR and at least two morphological features of RHD of the MV 
B) MS mean gradient ≥ 4 mmHg* 
C) Pathological AR and at least two morphological features of RHD of the AVǂ  
D) Borderline disease of both the AV and MV§  
2. Borderline RHD (either A, B or C) 
A) At least two morphological features of RHD of the MV without pathological MR or MS 
B) Pathological MR 
C) Pathological AR 
3. Normal echocardiographic findings (all of A, B, C and D) 
A) MR that does not meet all four Doppler echocardiographic criteria (physiological MR) 
B) AR that does not meet all four Doppler echocardiographic criteria (physiological AR) 
C) An isolated morphological feature of RHD of the MV (for example, valvular thickening) without 
any associated pathological stenosis or regurgitation 
D) Morphological features of RHD of the AV (for example, valvular thickening) without any 
associated pathological stenosis or regurgitation 
Echocardiographic criteria for individuals aged > 20 years 
Definite RHD (either A, B, C or D) 
A) Pathological MR and at least two morphological features of RHD of the MV 
B) MS mean gradient ≥ 4 mmHg* 
C) Pathological AR and at least two morphological features of RHD of the AV, only in individuals aged 
< 35 yearsǂ  
D) Pathological AR and at least two morphological features of RHD of the MV 
*Congenital MV anomalies must be excluded. Furthermore, inflow obstruction due to non-rheumatic mitral annular calcification must be 
excluded in adults. ǂBicuspid AV, dilated aortic root, and hypertension must be excluded. §Combined AR and MR in high prevalence 
regions and in the absence of congenital heart disease is regarded as rheumatic. 
Abbreviations: Aortic regurgitation (AR), aortic valve (AV), mitral regurgitation (MR), mitral stenosis (MS), mitral valve (MV), rheumatic 
heart disease (RHD), World Heart Federation (WHF) 
 
Use of different criteria to define RHD on echocardiography essentially render the 
comparison of epidemiological studies invalid.[50] The 2012 WHF criteria by virtue of being 
a standardised set of diagnostic criteria have since enabled the comparability, consistency, 
and reproducibility of findings.[51] In turn standardisation has increased specificity for 
definite RHD diagnosis as well as raised the threshold for borderline RHD thereby reducing 
the false positive rate.[50] 
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Regardless of the use and availability of increasingly accurate diagnostic tools, many people 
still present in the advanced stages of disease and without an associated history of ARF. In 
such situations, reliance on a preceding diagnosis of ARF in all at risk individuals will 
inevitably result in a failure to detect a considerable number of people who might otherwise 
profit from secondary prophylaxis.[52] For this reason early screening remains an essential 
tool in the cardiologist’s arsenal against the continued persistence of RHD. 
8. SCREENING 
The primary purpose of screening is to identify the presence of disease or a preceding 
condition in seemingly well individuals.[29] Five disease specific criteria need to be satisfied 
before population level screening can be considered a suitable preventive measure. First; 
there needs to be clear evidence of a significant disease burden, second; the condition in 
question needs to present with an initial latent stage, third; the latent stage of the condition 
needs to be detectable by appropriate tests, fourth; the latent stage must be able to be 
treated with adequate therapy, and finally; there must be clear evidence that early 
intervention at the latent stage improves prognostic outcomes.[39,51,53] 
At first glance, echocardiographic screening for RHD appears to meet the first two criteria 
unequivocally. There is an obvious burden of disease, particularly in the developing world 
and RHD does have a well-documented latent stage often referred to as subclinical, clinically 
silent or borderline disease.[51,53] The remaining criteria, however, remain insufficiently 
met due to gaps in knowledge.[35] In this regard it has been argued that a number of issues 
still need to be addressed prior to the endorsement of wide scale echocardiographic 
screening.[50] 
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These include amongst others the continued obscurity of the natural history of both 
borderline RHD and definite RHD without a clear history of ARF.[52] While they are both 
variants of the disease it remains unclear as to whether secondary prophylaxis using long 
acting penicillin injections would slow disease progression as is the case with conventionally 
diagnosed RHD.[32,52] 
While the WHO has recommended screening for RHD in endemic areas since 2004 [6], 
researchers caution that prior to implementing wide scale echocardiographic screening 
programs, the impact on both heath care systems and populations alike must be carefully 
considered.[52] False positive diagnoses prompting the unwarranted initiation of long-term 
prophylaxis would add additional strain to health care systems as well as detrimentally 
impact on individuals. Moreover, there is little value in screening for RHD if insufficient 
resources and systems exist to provide the necessary follow-up and treatment.[52] 
8.1 Role and Value 
An unfortunate reality is that most people only present to care when their disease becomes 
symptomatic.[54] One of the reasons for this is the latent nature of RHD during the initial 
stages preceding the clinical period.[54,55] Screening for subclinical RHD is therefore 
directed at diagnosing RHD during its asymptomatic phase in order to initiate prophylaxis 
and potentially slow progression to overt clinical RHD.[32,56] However, in order to increase 
rates of early diagnosis more active surveillance systems and large scale screening 
programmes are needed in endemic areas.[35] 
Programmes reviewing secondary prophylaxis in mild ARF have demonstrated regression of 
valve lesions within 5-10 years.[57] Initiating secondary prophylaxis in early-stage RHD 
patients through targeted screening programmes thus has the potential of preventing, 
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stopping or even regressing further valve damage.[35] The value of screening for RHD is that 
cases of subclinical RHD might be detected early on thereby reducing the time to secondary 
prophylaxis and thus improving long term outcomes by effecting a delay in disease 
progression.[35,52] Furthermore, early disease detection has the potential to prevent many 
of the unwanted consequences associated with advanced RHD including the need for costly 
surgical interventions.[58] 
Historically cardiac auscultation has been the basis of screening for RHD in many developing 
countries.[59,60] However, the revelation that a large amount of subclinical RHD remains 
undetected when using cardiac auscultation alone has had major implications for this 
practice going forward.[5,30] Regrettably, the use of standard echocardiography for wide 
scale RHD screening in endemic areas continues to be restricted primarily as a result of the 
high costs involved and scarcity of trained personnel.[5,58,61] 
8.2 Handheld Echocardiography 
Recently handheld echocardiography or HAND, shown in figure 3 below, has become widely 
available with a variety of clinical uses.[6] Similar diagnostic accuracy has already been 
demonstrated in a number of studies assessing the value of HAND as a screening tool and 
the device has been shown to significantly improve the detection of RHD over auscultation 
alone in preliminary studies.[5,6] On this basis it been suggested that these handheld 
devices could provide a more affordable and accessible alternative to standard 
echocardiography in screening for RHD.[51,52] 
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These new echocardiographic machines are light-weight, pocket-sized and able to fit in the 
palm of a hand making them highly portable and easily carried.[62] The devices are battery 
operated and offer real time imaging as well as the capacity to store and transfer 
information digitally.[63] An ability to accurately assess left ventricular function, visualise 
chamber size and rheumatic valves as well as rule out pericardial effusions [23] is 















Figure 3. Image of an ultra-portable hand held ultrasound device [65] 
8.3.1 Advantages 
The average cost of a handheld device is $5, 920 which is considerably less than larger 
machines such as the GE Vivid-I, GE Vivid-q and Philips CX50, which can cost upwards of $29, 
200 and as much as $42, 000.[65] In addition the handheld devices are light-weight and 
battery operated making them more portable than the standard machines which are heavy 
and require wired electricity.[66] Decreased costs coupled with increased portability provide 
opportunities for the decentralisation of echocardiographic based screening as well as other 
clinical applications, such as point-of-care use in intensive care and emergency settings.[23] 




The handheld devices are not without their limitations and a number of technical challenges 
impede their true value for screening. They were designed for sporadic rather than 
continuous use and run the risk of overheating if used uninterruptedly. Similarly, their 
relatively short battery life necessitates the availability and frequent replacement of 
batteries.[64] This is particularly limiting with respect to large screening programmes where 
lengthy use of the device could be required. 
Other limiting factors include the inability to manually enter patient information, poorer 
resolution, lack of spectral Doppler capabilities and fixed colour Doppler settings.[64] 
Specifically, a complete assessment of the left ventricle is impeded by the lack of spectral 
Doppler [63] whilst a tendency to overestimate valvular regurgitant jet lengths is an upshot 
of the unadjustable colour Doppler settings.[64] Overall these technical shortfalls limit the 
usefulness of handheld echocardiographic devices in terms of screening.[51] 
Due to these limited technical capacities, handheld devices are currently not endorsed as a 
substitute for standard echocardiography.[63] It is therefore also recommended that screen 
positive cases detected on HAND be re-examined with STAND for confirmatory 
diagnosis.[52] In light of this, researchers have urged that the utility of HAND for both 
screening and clinical practice should remain a topic of research.[52] 
8.3.3 Opportunities for future research and further development 
Researchers have suggested that further improvements to incorporate spectral Doppler 
capabilities in handheld devices would expand the device’s suitability for screening 
purposes.[51,58] Additional developments to improve the functionality of handheld devices 
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include better battery life, frequency shifting abilities and manual entry of patient data.[64] 
It has also been suggested that a modification of the WHF criteria for use with HAND may 
increase accuracy for the detection of RHD.[58] 
Increasingly, the role of echocardiographic screening has passed to non-experts using a 
simplified set of diagnostic criteria specific to HAND. [64] It is clear that the feasibility of 
wide scale screening using echocardiography depends on the success of task-shifting.[58] 
For task-shifting to succeed, standardised training programs for non-experts will need to be 
developed, tested and validated.[58,64] Whilst handheld echocardiography signifies 
encouraging progress, it is clear that more research is required before advocating its use in 
wide scale echocardiographic screening programs.[64] 
9. CONCLUSION 
The enduring challenge of RHD is not due to a lack of understanding of how to control and 
prevent the disease. Rather it is a result of the failure to effectively implement wide scale 
prevention and treatment strategies.[21] Screening for asymptomatic disease is one of the 
methods employed for early detection and treatment, despite some uncertainty regarding 
long-term effects on prognosis and disease progression. Yet, the accurate detection of 
subclinical RHD in children and adolescents remains hampered by the cost of diagnostic 
machinery and scarcity of trained personnel in many endemic areas.[67] Alternative RHD 
screening tests which are accurate, affordable and user-friendly are therefore needed. 
Handheld echocardiography is a non-invasive, safe, portable and relatively inexpensive 
device which has been presented in recent publications to be a promising alternative to 
standard echocardiography as a first line screening test.[5,6] Due to diminished cost and 
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ease of transportation, the use of HAND over STAND has the potential to increase the 
accessibility of echocardiographic screening in LMICs where the disease remains 
endemic.[5] However, for HAND to be considered as a suitable replacement for STAND in 
the context of RHD screening, the device’s accuracy needs to be at least similar to that of 
STAND. A systematic review of the diagnostic accuracy of handheld echocardiography for 
the detection of subclinical RHD is therefore proposed. 
Findings from the proposed review could provide insight into targeted screening-based 
intervention strategies as well as open up avenues for further research. The generation of 
new quantitative evidence will allow clinicians and guideline developers to establish a set of 
evidence-based criteria for diagnosing RHD using handheld echocardiography. Ultimately, 
this will improve the management of patients with the disease, as effective treatment of 
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Handheld echocardiography presents an opportunity to address the need for more cost-
effective methods of detecting rheumatic heart disease (RHD) in resource-limited and 
remote settings. This systematic review, therefore, sought to summarise the accuracy of 
handheld echocardiography which, if shown to be sufficiently similar to that of the current 
gold standard, could usher in a new age of RHD screening in endemic areas.  
Methods 
A search of the electronic sources; PubMed, Scopus, Web of Science and EBSCOhost without 
language restriction was performed to identify studies published from 2012 onwards. We 
included all studies assessing the accuracy of handheld echocardiography for RHD detection 
in children and adolescents living in RHD endemic areas when the reference standard 
constituted standard echocardiography performed by an experienced cardiologist in 
conjunction with the 2012 World Heart Federation (WHF) criteria.  
Data collection and analysis 
Two authors independently assessed the methodological validity and quality of included 
studies against review specific QUADAS-2 criteria and extracted information on metrics of 
diagnostic accuracy. A meta-analysis was conducted to produce summary results of 
sensitivity and specificity using the HSROC method. Forest plots of sensitivity and specificity 
as well as scatter plots in Receiver Operating Characteristic (ROC) space in combination with 
subgroup analyses were used to investigate heterogeneity for the categorical covariates; 
geographic location, echocardiographer expertise and HAND protocol. Publication bias was 
not investigated.  




We included seven studies, five of which were from African countries. The average 
prevalence of any RHD (definite or borderline) for six of the seven included studies was 12% 
(95% CI: 7% - 18%). Handheld echocardiography was most accurate in detecting definite 
RHD only but demonstrated poor accuracy for the detection of borderline RHD only. 
Nevertheless, the main findings, from seven included studies, provide some evidence for the 
potential of handheld echocardiography to increase access to echocardiographic screening 
for RHD in resource limited and remote settings. 
Strengths and limitations 
We have evaluated and summarised the accuracy of handheld echocardiography for the 
detection of RHD in endemic areas, making the review relevant to current global agendas. 
The results of this review are also highly applicable for use in endemic areas for which 
screening programmes are frequently targeted. Overall methods of study design and 
conduct were insufficiently reported according to current standards which limited the scope 
of this review by restricting the number of subgroup and sensitivity analyses able to be 
performed. 
Author’s conclusions 
This review provides a summary of the accuracy of handheld echocardiography for the 
detection of RHD in children and adolescents. Among the three disease categories, 
handheld echocardiography was most accurate in detecting definite RHD only. The device 
proved less accurate in detecting any RHD (definite or borderline) and demonstrated poor 
accuracy for the detection of borderline RHD alone.  
Keywords Rheumatic heart disease, echocardiography, screening, diagnostic accuracy 




Rheumatic heart disease (RHD) is an acquired permanent heart valve condition which 
results from an atypical immune reaction to group A streptococcal (GAS) infection typically 
occurring in childhood.[1,2] Disease progression leading to chronic RHD can result in 
irreversible heart valve damage, cardiac failure, stroke and premature death.[3,4] RHD is, 
however, a preventable and treatable chronic condition which mostly affects disadvantaged 
populations.[3,5]  
Significantly, ARF may go undiagnosed and RHD can remain asymptomatic for many years, 
particularly during the initial stages thereby hindering the timely implementation of 
penicillin prophylaxis.[6] Echocardiographic screening in order to identify those with 
subclinical disease has been advocated as a means to support secondary prevention and 
potentially slow disease progression to overt clinical RHD.[7,8] Yet the feasibility of wide 
scale echocardiographic screening remains hindered by high costs and the dearth of trained 
personnel.[9]  Alternative screening tests for RHD which are both accurate and affordable 
are therefore needed in many endemic areas.  
Handheld echocardiography (HAND) is a non-invasive, safe, highly portable and 
comparatively less expensive device which has been presented in recent publications to be a 
promising alternative to standard echocardiography (STAND) despite some limitations such 
as the lack of spectral Doppler capabilities.[10,11] For HAND to be considered a suitable 
replacement for standard echocardiography, the device’s accuracy needs to be similar to 
that of STAND. However, a slightly lower accuracy would still be acceptable if the device can 
be unequivocally shown to be less costly, more portable, and easier to use and interpret as 
well as logistically less demanding overall.  
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We conducted a systematic review and meta-analysis of studies assessing the diagnostic 
accuracy of handheld echocardiography for the detection of RHD in children and 
adolescents. The findings of this review may offer direction to guideline developers as well 
as assist with the identification of gaps in diagnostic testing for RHD in endemic areas.  
2. METHODS 
This systematic review was prepared according to the Preferred Reporting Items for a 
Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) 
guidelines (see Appendix 5 for the Checklist).[12] The protocol for this review is registered 
with the International Prospective Register of Systematic Reviews (PROSPERO) under the 
registration number CRD42016051261 and is currently in press with BMJ Open. Section 4 in 
Part A describes the methods used in this review in detail. 
3. RESULTS 
3.1 Results of the Search 
Results of the literature search are reported in accordance with the PRISMA Statement and 
the study selection process is illustrated in figure 1 below.[13] The search strategy yielded a 
total of ninety two records, of which nine were duplicates. Of the remaining eighty three 
records, a total of sixty seven were excluded based on title or abstract leaving sixteen 
articles for full-text review. Nine of the sixteen remaining studies were then excluded on the 
basis of a full-text review. Seven studies which met the predefined eligibility criteria were 
included in this review. 
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*Reasons for exclusion on full-text review can be found in the table of excluded studies 
 
# of records identified through 
database searching 
(n = 92) 
# of records after duplicates 
removed 
(n = 83) 
# of titles (26) 
and abstracts 
(41) excluded 
(n = 67) 
# of duplicates 
removed 
(n = 9) 
PubMed  
(n = 57) 
Scopus  
(n = 3) 
EBSCOHost  
(n = 4) 
ISI Web of 
Science  
(n = 28) 
# of titles & abstracts 
screened 
(n = 83) 
# of full-text articles 
assessed for eligibility 
(n = 16) 
# of full-text 
articles excluded*  
(n = 9) 
# of studies included in 
quantitative synthesis  
(n = 7) 
# of additional records identified 
through other sources 
(n = 0) 
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3.1.1 Included studies 
A summary of notable characteristics of all included studies [10,14–19] is shown in table 1 
below. One study did not avoid a case-control design, however cases and controls were 
sampled from the same population. Research has shown that case-control studies which use 
alternative diagnosis controls, controls from non-endemic areas or confirmed disease-free 
(healthy) controls tend to overestimate specificity.[20] Significantly, all but two studies were 
conducted in Africa. Screening was performed in RHD endemic areas among children and 
adolescents with most studies being school-based. Combined, all seven studies included a 
total of 5525 participants of which 54% were female. The pooled mean age of participant’s 












































“Half (n=65) of the cohort were asymptomatic Ugandan 
school children who took part in an echo based screening 
study at their school. The other half (n=60) were patients 
presenting for follow up as part of the Ugandan RHD registry 
project.”[15] 









A random 10% subset of the 
entire sample plus any child 
with mitral or aortic 
regurgitation were 
preselected  to receive HAND  
"Government schools in Gulu, Uganda, were evaluated and 
five were selected to ensure adequate population 
numbers."[19] 














A subset of the sample 
containing all STAND 
abnormals plus a random 
25% of all STAND normals 
were preselected for HAND 
“The study was conducted in the context of an existing 
school-based RHD screening program-PROVAR. The PROVAR 
study selection criteria were asymptomatic children aged 
between 5 and 18 years old attending public schools of 
underserved areas in the State of Minas Gerais. This study 
included 5 schools from Belo Horizonte as testing sites.”[17] 









A random 10% subset of the 
entire sample were 
preselected  to receive both 
HAND and auscultation  
“Children attending 5 different schools in Gulu, Uganda were 
eligible for inclusion.”[10] 











“All fourth grade (aged 9-10 years) children attending local 
primary schools in Nouméa, the capital city and its suburbs 
were eligible.”[16] 










“All students attending 2 public primary schools in Gulu, 
Uganda were eligible for inclusion.”[18] 











"Cases were scholars previously diagnosed with 
asymptomatic RHD on screening echocardiography with 
persistent disease. Controls were normal healthy scholars 
previously enrolled in the original screening study who were 
matched for age, school grade, and residential area."[14] 
93 68.8 17¥† -  
Total      5525 54 10.8 ±2.1 
¤ According to the World Bank’s economic classification system 
¥ excluded from pooled mean & SD calculations (incomplete or incomparable data) 
† median age (mean age not available) 
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A summary of index test details is included in table 2 below. All seven included studies used 
the same make of handheld device; the Vscan machine (General Electric, Medical Systems, 
Milwaukee, Wisconsin, USA) paired with a 1.7 - 3.4 MHz transducer. These machines 
provide both two-dimensional (2D) and colour imaging on an integrated 8.9cm 
display.[16,19]  Frame rates range from 25 to 30 Hz for greyscale imaging and 12 to 16 Hz 
for colour Doppler.[15,18] Vscan machines are however limited by a lack of spectral Doppler 
capabilities.[19] The majority of included studies evaluated the accuracy of handheld 
echocardiography when performed and interpreted by experts whereas only three studies 
assessed the device’s performance in the hands of briefly trained non-experts.  
 












paired with a  
1.7 - 3.4 MHz 
transducer 
expert later/offlineǂ  MR > 2cm & AR > 1cm 
Beaton, 2015[19] expert later/offlineǂ 
MR ≥ 2cm, AR ≥ 1cm & 
thickness of anterior 
mitral leaflet ≥ 3mm 
Beaton, 2016[17] non-expert on-site§ MR ≥ 1.5cm &/or any AR  
Godown, 2015[10] expert unclear  MR > 2cm & AR > 1cm 
Mirabel, 2015[16] non-expert on-site§ MR ≥ 1.5cm &/or any AR 
Ploutz, 2016[18] non-expert on-site§ MR ≥ 1.5cm &/or any AR 
Zühlke, 2016[14] expert on-site§ MR ≥ 2cm 
§ on-site: refers to interpreting images at the time of screening / evaluation 
ǂ later/offline: refers to the use of Vscan Gateway software to interpret images post screening 
 
3.1.2 Excluded studies 
Nine studies [9,21–28] were excluded during the full-text screening phase as shown in figure 
1. Reasons for exclusion are listed in table 3 with the most common being abstract only 
publication and the use of ineligible reference or index tests. One study was excluded on 
account of using duplicate data from four other included studies whilst another was not a 
study of diagnostic accuracy.  
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Table 3. Characteristics of excluded studies [ordered by year of study] 
Study Reason for Exclusion 
Mirabel, 2012[21] Ineligible reference standard (2012 WHF criteria not used)  
Colquhoun, 2013[22] Ineligible reference standard (2012 WHF criteria not used) 
Godown, 2014[23] Published as an abstract ahead of full-text publication in 2015 
Lu, 2014[24] Published as an abstract ahead of full-text publication in 2015 
Lu, 2015[9] Test threshold(s) not specified a-priori 
Engelman, 2016[25] Ineligible index test and test threshold(s) not specified a-priori 
Hardie, 2016[26] Published as an abstract on a poster only with no full-text available 
Lopes, 2016[27] Not a test accuracy study 
Diamantino, 2017[28] Uses duplicate data 
 
3.2 Methodological Quality of Included Studies 
A summary of the assessment of methodological quality of all included studies is illustrated 
in table 4 and figure 2 below. Overall only two of the seven included studies were assessed 
as having a low risk of bias while the risk of bias in the remaining five was unclear. Two 
studies had participant selection bias concerns. Of these both failed to adequately describe 
participant enrolment methods whilst one study also did not avoid a case-control design.  
The risk of bias in terms of flow and timing was unclear in three studies. Of these, two did 
not include all participants in the analysis while the time interval between the index and 
reference test was unclear in one study. Of the two studies which did not include all 
participants in the analysis, not all participants received an index or reference test in one 
whilst technical difficulties precluded the inclusion of all participants in the analysis of the 
other study. Overall, time intervals between index and reference standard tests were poorly 
described. Likewise, reporting of quality control of the index test was uniformly poor across 
all included studies. Concerns regarding applicability were low in all seven studies.











Table 4. Summary of quality appraisal of included studies 
















Beaton, 2014[15] Unclear Low Low Low Unclear  Beaton, 2014[15] Low Low Low Low 
Beaton, 2015[19] Low Low Low Unclear Unclear  Beaton, 2015[19] Low Low Low Low 
Beaton, 2016[17] Low Low Low Low Low  Beaton, 2016[17] Low Low Low Low 
Godown, 2015[10] Low Low Low Unclear Unclear  Godown, 2015[10] Low Low Low Low 
Mirabel, 2015[16] Low Low Low Low Low  Mirabel, 2015[16] Low Low Low Low 
Ploutz, 2016[18] Low Low Low Unclear Unclear  Ploutz, 2016[18] Low Low Low Low 
Zühlke, 2016[14] Unclear Low Low Low Unclear  Zühlke, 2016[14] Low Low Low Low 
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We evaluated the accuracy of handheld echocardiography according to three disease 
categories; any RHD (borderline or definite), definite RHD only and borderline RHD only. The 
any RHD category was considered the main meta-analysis as it had the most complete data. 
We were unable to extract metrics of diagnostic accuracy for the definite and borderline 
RHD only categories from Beaton, 2016 and therefore excluded this study from these meta-
analyses. We chose to use Nurse A’s results for Mirabel, 2015 since Nurse A and Nurse B 
both interpreted the same HAND images thereby preventing the pooling of data.  
Data from Zühlke, 2016 were included in the analysis and synthesis of data even though the 
age range of participants fell outside the predefined range for eligibility. It was determined 
that this study should be included, regardless, since the data overall were quite few and the 
variation in age was not significant enough to warrant exclusion. However, data from 
Zühlke, 2016 were excluded from all summary estimates of disease prevalence since this 
study used a nested case-control design which predetermines disease prevalence by design.  
The Hierarchical Summary Receiver Operating Characteristic (HSROC) model was used for 
meta-analysis as it accounts for variations in test thresholds. We were only able to examine 
relationships between test accuracy and the categorical covariates; echocardiographer 
expertise, HAND protocol and geographic location. We were unable to perform meta-
regression for the covariates; age and sex due to insufficient data.[29] Heterogeneity was 
examined for the main meta-analysis only. All plots were generated using the Review 
Manager (RevMan) software package, version 5.3.[30] Meta-analysis was performed using 
SAS® software, version 9.4.[31] The overall findings for each of the three disease categories 
are presented in detail below and a summary of the key findings can be found in table 7. 











3.3.1 For any RHD 
A total of seven evaluations of handheld echocardiography for any RHD were performed 
with data from seven studies and a total of 5506 participants. Pooled prevalence of any RHD 
(definite or borderline) from six included studies was 12% (95% CI: 7% - 18%). The forest 
plot (figure 3) reveals little variation in estimates of sensitivity and specificity. The HSROC 
plot (figure 4) reveals moderate accuracy of the test as most study points lie close to the 
upper left corner of the plot. Meta-analytical sensitivity and specificity (95% confidence 


















The blue squares represent the sensitivity and specificity of each study and the black line its corresponding 95% confidence interval. 
 
Figure 4. Summary ROC plot of sensitivity versus specificity of handheld echocardiography for any RHD. 


























Abbreviations: ROC, Receiver Operating Characteristic; HSROC, Hierarchical Summary ROC 
 










3.3.2 For definite RHD 
A total of six evaluations of handheld echocardiography for definite RHD were performed 
with data from six studies and a total of 4779 participants. Pooled prevalence of definite 
RHD from five included studies was 5% (95% CI:  2% - 10%). The forest plot (figure 5) reveals 
some variation in estimates of specificity while estimates of sensitivity are largely 
homogenous with the exception of a single outlier. The HSROC plot (figure 6) reveals good 
accuracy of the test as most study points lie in the upper left corner of the plot. Meta-
analytical sensitivity and specificity (95% CI) of data at mixed thresholds were 93% (85% to 
















The blue squares represent the sensitivity and specificity of each study and the black line its corresponding 95% confidence interval. 
 
Figure 6. Summary ROC plot of sensitivity versus specificity of handheld echocardiography for definite RHD. 































Abbreviations: ROC, Receiver Operating Characteristic; HSROC, Hierarchical Summary ROC 
 











3.3.3 For borderline RHD  
A total of six evaluations of handheld echocardiography for borderline RHD were performed 
with data from six studies and a total of 4957 participants. Pooled prevalence of borderline 
RHD from five included studies was 18% (95% CI: 7% - 31%). The forest plot (figure 7) reveals 
some variation in estimates of specificity while estimates of sensitivity are largely 
homogenous with the exception of a single outlier. The HSROC plot (figure 8) reveals poor 
accuracy of the test as most study points lie close to the diagonal line. Meta-analytical 
sensitivity and specificity (95% CI) of data at mixed thresholds were 64% (40% to 88%) and 















The blue squares represent the sensitivity and specificity of each study and the black line its corresponding 95% confidence interval. 
 
Figure 8. Summary ROC plot of sensitivity versus specificity of handheld echocardiography for borderline RHD. 
































Abbreviations: ROC, Receiver Operating Characteristic; HSROC, Hierarchical Summary ROC 




We evaluated the accuracy handheld echocardiography for three distinct disease categories 
and found that, overall, the test was most accurate for detecting definite RHD only, 
moderately accurate for detecting any RHD (definite or borderline) and least accurate for 
detecting borderline RHD. A summary of the accuracy estimates produced by meta-analysis 
using the HSROC method is shown in table 5 below.  
Table 5. Overall meta-analysis 
Test N Sensitivity (95% Crl) Specificity (95% CrI) 
Any RHD  7 80.79% (76.39 – 85.19) 89.1% (84.78 – 93.41) 
Definite RHD 6 93.23% (85.41 – 100) 90.82% (85.5 – 96.14) 
Borderline RHD 6 63.61% (38.82 – 88.39) 83.34% (70.02 – 96.65) 
Abbreviations: N, number of studies; Crl, credible interval 
 
3.4 Investigations of Heterogeneity  
Heterogeneity or variation between studies was investigated both visually as well as 
through subgroup and sensitivity analysis for the main meta-analysis (any RHD) only.  
3.4.1 Co-variates in the models 
We were only able to use three of the five pre-specified covariates to investigate 
heterogeneity due to insufficient data. Pre-identified potential sources of heterogeneity 
which were investigated included the categorical covariates; HAND echocardiographer 
expertise (expert vs non-expert), geographic location (high vs low and middle income 
countries) and HAND protocol (single vs multiple views).  
For the covariate; geographic location and in terms of the World Bank’s economic 
classification system South Africa and Brazil are classed as upper middle income countries 
whereas Uganda is classified as a low income country and New Caledonia a high income 




country. Of the seven included studies, six were conducted in either low or middle income 
countries while only one was conducted in a high income country.  
For the covariate; echocardiographer expertise, only three studies evaluated the accuracy of 
handheld echocardiography when performed and interpreted by trained non-experts while 
the remaining four assessed its accuracy in the hands of experts. For the covariate; HAND 
protocol, only one of the seven included studies used a single view protocol whereas the 
rest used multiple view protocols.  
3.4.2 Subgroup and sensitivity analyses 
A subgroup analysis was performed to investigate potential sources of heterogeneity. We 
were only able to perform this analysis for the any RHD category as the data were too few 
to enable model convergence for the definite and borderline RHD only categories. Since no 
studies were found to have a high risk of bias we did not explore the effect of excluding such 
studies on the accuracy of summary estimates; sensitivity and specificity. We did not 
investigate publication bias as methods of assessing publication bias for studies of 
diagnostic accuracy are still being developed. While the Deeks test has been suggested for 
use in diagnostic accuracy studies, the test has low power for detecting asymmetry in funnel 
plots, particularly when a large amount of heterogeneity is present.[32]     
 Modelling the effects of the covariates on overall sensitivity and specificity in the statistical 
models revealed a general increase in sensitivity and a decrease in specificity for the 
covariates; geographic location, echocardiographer expertise and HAND protocol, as shown 
in table 6. More specifically, in the low and middle income subgroup, sensitivity (80.41% vs 
83.31%) was lower and specificity (89.09% vs 88.12%) higher compared to the overall 




analysis. Both sensitivity (81.8% vs 80.76%) and specificity (92.11% vs 85.71%) were higher 
for any RHD detection using handheld echocardiography when tests were performed and 
interpreted by experts compared to non-experts. In the multiple view protocol subgroup, 
both sensitivity (80.12% vs 83.99%) and specificity (87.38% vs 88.79%) were lower 
compared to the overall analysis. 
Table 6. Sources of heterogeneity for handheld echocardiography for any RHD 




Sensitivity (95% Crl) 
Median Pooled 
Specificity (95% Crl) 









1 - - 
  
Low and middle 
income countries 




Overall  85.23% (70.31 – 100) 85.01% (78.42 – 91.59) 
  Expert 4 81.8% (75.32 – 88.28) 92.11% (85.98 – 98.25) 
  Non-expert 3 80.76% (73.18 – 88.33) 85.71% (79.91 – 91.51) 
 HAND Protocol Overall  83.99% (79.57 – 88.41) 88.79% (84.57 – 93) 
  Single view studies 1 - - 
  Multiple view studies  6 80.12% (75.53 – 84.71) 87.38% (83.94 – 90.82) 
Abbreviations: HAND, handheld echocardiography; Crl, credible interval; n, number of studies; N, total number of included studies 
*There was insufficient data to pool results for high income countries 
4. DISCUSSION 
4.1 Summary of Main Findings 
Data from seven studies involving a total of 5525 participants overall were used in this 
review. Six of the seven studies were conducted in low or middle income countries and all 
with the exception of one were based in field settings (schools and communities).  




All studies were conducted in RHD endemic areas and all studies used the Vscan machine 
paired with a 1.7 – 3.4 MHz transducer as the index test. The main findings, including 
average accuracy estimates for each of the three disease categories, are reported in table 7 
below.  
Briefly, our findings suggest that if handheld echocardiography is used for the detection of 
definite RHD only, 93% of truly diseased individuals will screen positive, whilst 91% of 
individuals without definite RHD will be correctly screened as normal. If handheld 
echocardiography is used to screen for any RHD, only 81% of those with definite or 
borderline disease will be correctly identified as such by the screening test whereas 89% of 
truly disease free individuals will test negative. In contrast, if handheld echocardiography is 
used to screen for borderline RHD only, the test will only correctly identify 64% of those 
with borderline RHD as such while 83% of individuals without borderline RHD will be 
correctly identified as normal by the screening test. We then applied the summary 
estimates to a hypothetical cohort of 1000 patients and discuss the findings in detail 
following the summary of findings table. 




Table 7. Summary of findings 
What is the diagnostic accuracy of handheld echocardiography in detecting any rheumatic heart disease (definite or borderline)? 
Patients/Population People residing in areas endemic for rheumatic heart disease (7 out of 7 studies) 
Prior testing with echo Yes (2 studies), No (5 studies) 
Settings 
6 out of 7 screening studies were field setting (communities and schools) based while 1 study was half 
registry follow-up, half school based.  
5 of the 7 studies were conducted in Africa with 4 of the 5 from Uganda.  
Index test(s) General Electric (GE) Vscan handheld machine (7 out of 7 studies) 
Reference standard 
Standard echocardiography (2D, continuous-wave, and colour-Doppler echocardiography) performed 
by an experienced imager and in conjunction with the 2012 WHF criteria (7 out of 7 studies). 
Machine brands included; 
GE Vivid-I ultrasound machine (2 out of 7 studies) 
GE Vivid-Q ultrasound machine (2 out of 7 studies) 
Philips CX-50 ultrasound machine (1 out of 7 studies) 
Either a GE Vivid-I or Q or Philips CX-50 ultrasound machine (2 out of 7 studies) 
Importance 
This test is being used as first line replacement for standard echocardiography in disease screening 
programmes for RHD, as it is comparably inexpensive, quick, user friendly, easy to interpret, and may 
have similar sensitivity to standard echocardiography.  
Studies 
Cross-sectional (n = 5), spiked cohort (n = 1) and nested case-control (n = 1) studies. More than half (n = 
4) of all included studies did not explicitly state the study design used and were thus assigned a study 
design based on other reported characteristics and participant enrolment methods used.  
Quality concerns 
Poor reporting of study design, participant characteristics and pre-test probability were common 
concerns. For the majority of studies the risk of bias assessment was unclear in terms of the QUADAS 
domains ‘patient selection’ and ‘flow and timing’. Concerns regarding applicability were low in all 
included studies. 
Test types  
Number of 
participants* (N) 
Summary Estimates  
(95% credible CI) 
Test result 
Prevalence in 1000 people tested 






(76.39 – 85.19)  
 
Specificity; 89.1% 
(84.78 – 93.41) 
All cases  
(TPs + FNs) 
25 50 100 
Missed cases 
(FNs) 
5 10 19 
False positives 
(FPs) 
106 104 81 
All positives  
(TPs + FPs) 






(85.41 – 100)  
 
Specificity; 90.82% 
(85.5 – 96.14) 
All cases  
(TPs + FNs) 
25 50 100 
Missed cases 
(FNs) 
2 3 7 
False positives 
(FPs) 
90 87 83 
All positives  
(TPs + FPs) 






(38.82 – 88.39)  
 
Specificity; 83.34% 
(70.02 – 96.65) 
All cases  
(TPs + FNs) 
25 50 100 
Missed cases 
(FNs) 
9 18 36 
False positives 
(FPs) 
162 158 150 
All positives  
(TPs + FPs) 
178 190 214 
Abbreviations: CI, confidence interval; N, number of studies; TPs, true-positives; FPs, false-positives; TNs, true-negatives; FNs, false-negatives 
* Excluding participants with other diagnoses on STAND 




For any RHD diagnosis in apparently healthy children and adolescents the pooled sensitivity 
and specificity (95% Crl) of handheld echocardiography were 81% (76% to 85%) and 89% 
(85% to 93%) respectively. Given these estimates and in hypothetical cohort of 1000 
children and adolescents with a prevalence of 5%, handheld echocardiography will correctly 
detect any RHD in 40 people, fail to detect ten cases while 104 people would receive 
unnecessary treatment or be needlessly referred for further testing. 
For definite RHD diagnosis in apparently health children and adolescents the pooled 
sensitivity and specificity (95% Crl) of handheld echocardiography were 93% (85% – 100%) 
and 91% (86% to 96%). Given these estimates and in a hypothetical cohort of 1000 children 
and adolescents with a pre-test probability of 5%, handheld echocardiography will correctly 
detect definite RHD in 47 people, while only three will miss treatment and 87 people will 
receive unnecessary treatment or be needlessly referred or further testing. 
For borderline RHD diagnosis in apparently healthy children and adolescents the pooled 
sensitivity and specificity (95% Crl) of handheld echocardiography were 64% (39% to 88%) 
and 83% (70% to 97%). Given these estimates and in a hypothetical cohort of 1000 children 
and adolescents with a pre-test probability of 5%, handheld echocardiography will correctly 
detect borderline RHD in 32 people, while eighteen people will miss treatment and 158 
people will receive unnecessary treatment or be needlessly referred for further testing. 
While only seven additional cases would be missed if HAND was used to screen for any RHD 
as opposed to definite RHD only, an extra seventeen healthy people would be incorrectly 
classified and another seven people would be missed by the test. However, given the 
implicit value of identifying borderline cases in order to initiate prophylaxis, this trade off 
could be considered acceptable. 




4.2 Strengths and Weaknesses of this Review 
4.2.1 Strengths 
We have evaluated and summarised the accuracy of handheld echocardiography for the 
detection of RHD in endemic areas, making the review relevant to current global agendas. 
This review also serves to highlight the existing gaps in evidence for which further research 
could be beneficial. We did not impose a search filter or any limits in terms of language 
during the literature search so as to minimise the chance of missing studies. Data extraction 
was performed by two independent reviewer authors thereby reducing the risk of bias.  
4.2.2 Weaknesses 
There were a number of shortcomings of this review which include the following. 
Eligibility 
We were unable to include studies which used STAND in conjunction with criteria other than 
the 2012 WHF criteria as the reference standard which limited the number of studies 
eligible for inclusion. 
Quality of included studies 
Insufficient reporting of participant characteristics and study methods including study 
design, participant selection and test timing restricted our ability to adequately assess risk 
of bias and investigate potential sources of heterogeneity. 
Paucity of data 
Insufficient data as well as the presentation of aggregate data limited the scope of our 
investigations of heterogeneity and the small number of included studies prevented us from 




performing meta-regression. Overall, the findings from this review may lack power due to 
the small sample size.  
4.3 Applicability of Findings to the Review Question 
Concerns regarding the applicability of included studies to the review question were 
assessed as being low according to review-specific QUADAS-2 criteria. Since all but one 
study were conducted in low or middle income countries, and all studies but one were 
conducted in field settings, the results of this review are applicable for use in endemic areas 
for which screening programmes are frequently targeted. However, our limited assessment 
of risk of bias and investigations into sources of heterogeneity such as age and gender due 
to insufficient and unreliable reporting may lessen the applicability of findings to the review 
question.  
In the context of disease control programmes, being able to demonstrate variation in test 
accuracy associated with factors such as age and gender would be beneficial for policy 
makers. Fully understanding included studies’ risk of bias would also assist in objectively 
assessing the strength of evidence. For these reasons, prospective authors of diagnostic test 
accuracy studies are urged to make use of the Standards for Reporting of Diagnostic 
Accuracy Studies (STARD) guidelines [33] when reporting methods of study design and 
conduct. 
5. CONCLUSION 
This review provides a summary of the accuracy of handheld echocardiography for the 
detection of RHD. In populations of children and adolescents living in RHD endemic areas, 
handheld echocardiography is both sensitive and specific for detecting definite RHD. The 




device is less accurate in detecting any RHD (definite or borderline) and demonstrates 
substandard accuracy for the detection of borderline RHD only. Nonetheless, this test may 
hold value as a replacement in terms of first line screening due to its high sensitivity for 
definite RHD detection and adequate accuracy for any RHD detection.  
5.1 Implications for Practice 
Handheld echocardiography demonstrates sufficient accuracy for any RHD detection and 
good accuracy for definite RHD detection when used as a screening tool, however, the 
device’s potential value in terms of diagnostics has yet to be established. We therefore posit 
that handheld echocardiography could be recommended as an acceptable replacement test 
for first line screening in endemic areas provided a standardised set of device specific 
diagnostic criteria are developed. 
Another key consideration is the applicability of these findings for recommendations for 
integrating screening into routine clinical practice. A recent publication has reviewed the 
cost-effectiveness of screening in high-risk populations [34] and determined that screening 
all indigenous Australian 5 to 12 year-olds in half of their communities in alternate years 
was found to be cost-effective (incremental cost-effectiveness ratio less than AU$50 000 per 
disability-adjusted life-year averted), if RHD can be detected at least two years earlier; 
however, this result was sensitive to a number of assumptions, including the local costs and 
context.  
Other cost-effectiveness models have also suggested modestly improved outcomes at lower 
cost.[35] Neither of these studies included the significant cost-reduction using HAND instead 
of STAND, hence, we highly recommend adding a cost-effectiveness analysis into proposed 




new screening studies. In addition, these studies focused on small pockets within endemic 
countries, recommendations for wide scale population screening, despite the demonstrated 
diagnostic accuracy in our study, needs detailed further investigation.  
Finally, our findings demonstrate comparable results by non-experts, this has also been 
demonstrated in several other reports [22,36], but again there are no detailed cost-
effectiveness analyses using non-experts and HAND. 
5.2 Implications for Research 
The findings of this review highlight the need for a new set of evidence-based guidelines 
tailored to the capabilities of handheld echocardiography in order to maximise the device’s 
diagnostic potential. Further studies assessing the diagnostic accuracy of HAND when using 
a standardised protocol are needed as is further research into the feasibility, cost-
effectiveness and consequences of implementing wide scale RHD screening programs. 
Furthermore, the development of standardised training programs for non-experts is 
recommended as screening for RHD in endemic areas inevitably rests on the success of task 
shifting.[18] 
We conclude that while handheld echocardiography has been shown to be sufficiently 
accurate for the detection of RHD there is still a need for further research before its’ wide 
scale use can be endorsed. 
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1. General Information 











First Author:  Publication Year:                                       
Author Contact Details:  
References of Potentially 
Eligible Studies: (from the 
bibliography hand search)  
 
 
1a. Is this a study that examines 
the accuracy of tests for 











1b. If ‘No’ at item 1a., please 




2. Target Condition Page(s): 





Mixed definite & borderline
 





3. Study Population Page(s):  
3a. Country of study 
Please state the country or countries in which the study took place: 
 
3b. What is the estimated 
prevalence of RHD in the study 
area prior to the study? 












3d. Total number of participants  
included in study (sample size) 
No. of participants: 
Not reported
 No. of samples: 




3e. Proportion or number of 








FOR THE QUESTIONS 4 & 5, DRAWING A FLOW DIAGRAM OF THE STUDY MAY BE HELPFUL 
(space is provided on page 6 of this data extraction form) 
 
4. Patient Selection Page(s): 

















4b. What was the stage of disease 
at enrolment? 
Asymptomatic
   
Symptomatic
 










Case-control (cases & controls from the same population/nested)
  
Case-control (with healthy controls)  
EXCLUDE!  
Case-control (with alternative diagnosis controls)
EXCLUDE! 









4d. Was a case-control design 
avoided? 
Yes
                            
No
                        
Unclear
 
4e. Was either a consecutive or 
random sample of patients 
enrolled? (please specify which) 
Yes
                            
No




4f. Did the study avoid 
inappropriate exclusions? 
Yes
                            
No
                     
Unclear
 
4g. Could the selection of patients 
have introduced bias? (Please 
indicate the level of risk) 
Low risk of bias (if questions 4d and 4e were both answered 'yes')
 
High risk of bias (if both question 4d and 4e were answered 'no')
 
Unclear (any other combination of answers)
                                                              




4h. Is there concern that the 
included patients do not match 
the review question? (Please 
indicate the level of concern) 
 
Low concern (participants from endemic areas)
 
High concern (tourists, non endemic areas)
 
Unclear concern




5. Patient Flow and Timing Page(s): 
5a. Was there an appropriate 
interval between the index test 
and reference standard? 
Yes
                            
No
                           
Unclear
 
5b. Did all patients receive a 
reference standard test?  
(Focus on 2*2 table) 
Yes
                             
No
                             
Unclear
 
5c. Did all patients receive the 
same reference standard test? 
Yes
                             
No
                           
Unclear
 
5d. Were all patients included in 
the analysis? 
Yes
                            
No
                           
Unclear
 
5e. Could the patient flow have 
introduced bias? (Please indicate 
the level of risk of bias) 
 
Low (if questions 5a-d were all answered 'yes', or at least three were 
answered 'yes' and the other 'unclear')
High (if two or more of questions 5a-d were answered 'no')
 
Unclear (any other combination of answers)
                                                               
 
6. Index Test Page(s): 
6a. Please state index test’s name  
(i.e. brand name/manufacturer) 
and the person(s) performing and 
interpreting the test as well as the 
time at which interpretation 
occurred (i.e. on-site/at time of 







Time of interpretation: 
6b. Was a pre-specified set of 
diagnostic criteria or protocol 
used?  
Yes
   
No






6c. Was the HAND interpreter 
trained to use the protocol? If the 
HAND interpreter has prior 
experience/skill/expertise and 
training was not necessary please 
also select ‘Yes’. 
Yes
   
No





6d. What was the initial level of 
expertise of the HAND 
interpreter? 
 






6e. Was quality control done? 
(e.g. 10% of samples cross 
checked by another person) 
Yes
   
No






6f. Were the index test results 
interpreted without knowledge of 
the results of the reference 
standard? 
Yes
   
No











6g. If a diagnostic threshold was 
used was it pre-specified? 
Yes
   
No





6h. Could the conduct or 
interpretation of the index test 
have introduced bias? 
 
Low risk of bias (if questions 6b-g were all answered 'yes')
 
High risk of bias (if two or more of questions 6b-g were answered 'no')
Unclear (any other combination of answers)
     
                                                             
 
7. Reference Test Page(s): 
7a. Please state reference test’s 
name (i.e. brand name / 
manufacturer) and the person(s) 
performing and interpreting the 
test as well as the time at which 
interpretation occurred (i.e. on-
site / at time of screening or later 
/ offline) 










Time of interpretation: 
7b. Number of reference test 






7c. Was quality control done? 
(e.g. were 10% of samples cross 
checked by another person) 
Yes
     
No
      
Unclear






7d. Is the reference standard 
likely to classify the target 
condition? 
Yes
     
No





7e. Were the reference standard 
results interpreted without 
knowledge of the results of the 
index test? 
Yes
     
No
      
Unclear







7f. Could the reference standard, 
its conduct, or its interpretation 
have introduced bias? 
Low risk of bias (if questions 7c-e were all answered 'yes')
 
High risk of bias (if one or more of questions 7c-e were answered 'no')
Unclear (any other combination of answers)
                                                                 
 
8. Test Results Page(s): 
8a. Prevalence of disease based 
on STAND results: Please state 
mean and range/confidence 
intervals (for all who were 








8b. Severity of disease:  
Please state the disease severity 
according to assessment by 
STAND (only for those who 
received both HAND & STAND) 
 Not stated
 
8c. Missing Data:  
Yes
                                     








Were there missing, 
uninterpretable or unavailable 
results of the reference standard? 
 
Were there missing, 
uninterpretable or unavailable 
results of the index test? 
                                  
 
Yes
                                    






8d. Accuracy Results 
 Please calculate and list results of the index test below: TP,TN, FP, FN, Sens, Spec. 
 Please also indicate the main test threshold used to calculate the results. 
 If multiple thresholds have been used please indicate so in the comments box. 
 
Table A 
Test Test Threshold TP FP FN TN Sens Spec 
        
 
        
 
        













For questions 4 and 5, drawing a flow diagram of the study may be helpful. Flow diagrams of patient 
selection, flow and timing illustrate the number of patients who were eligible for the study, how 
many were actually recruited, the proportion of which received the index test as well as the 
proportion of which received the reference standard etc. In addition, the number of true and false 
positives and true and false negatives are also displayed. If necessary please draw a flow diagram for 








APPENDIX 2: BACKGROUND DOCUMENT TO THE DATA EXTRACTION FORM 
*NB: At the beginning of each section please write the page number(s) on which the majority of the 
information pertaining to that section was found. A space is provided next to the section heading for 
this. 
(1) GENERAL INFORMATION 
Publication type: Describe the type of publication, i.e.: full report, abstract, conference proceeding 
etc. 
Journal: Name of the journal in which the article is published (if published) 
Article title: Enter the title of the article 
First author: Enter the full name of first author 
Publication year: Enter the year in which the article was published 
Author contact details: Record the contact details of the corresponding author for future reference 
in instances where additional data needs to be obtained or questions clarified 
The following questions have activated checkboxes next to the responses. Please make your selection 
by clicking the appropriate checkbox. 
1a. Is this a primary study that examines the accuracy of tests for rheumatic heart disease (RHD)? 
Tick the appropriate box. If answered ‘no’, EXCLUDE the paper. This item is meant to enable the 
quick distinction between potentially relevant articles and articles that clearly have a different 
scope. If the article does not clearly evaluate the accuracy of tests as a primary or secondary 
objective you can tick ‘no’ and stop the data extraction exercise. If you are unsure please tick 
‘unclear’, comment on why you are unsure and then proceed with the data extraction exercise. 
1b. If the article does not evaluate accuracy tests for RHD, please describe what kind of article it 
is? 
Please describe what type of publication it is (e.g. narrative overview article, a purely prevalence 
study etc.) 
(2) TARGET CONDITION BEING EVALUATED 
2. Please indicate the target condition being evaluated in the study. 
[All studies should evaluate both borderline and definite in accordance with the 2012 WHF criteria] 
 





Please tick the appropriate box to indicate if the study evaluates either definite or borderline RHD or 
both as the condition of interest. If it doesn’t evaluate definite or borderline RHD but rather another 
condition; EXCLUDE the paper and add an explanation in the comment in the box provided. 
(3) STUDY POPULATION 
3a. Country of study 
Some studies may be carried out in one country or in multiple countries. Please state the country or 
countries in which the study was conducted. 
3b. What is the estimated prevalence of RHD in the study area prior to the study? 
Prior to the study commencing, the authors may state the estimated prevalence of RHD in the area 
or country of study. This estimated prevalence may be based on previous reports or other studies. If 
it is not reported please tick the box ‘Not reported’. 
3c. Age of participants 
Please indicate the mean or median and SD or range of the age of the study participants included in 
the study. Please state the measures that are reported in the study. If no measures were reported in 
the study, please tick the box ‘Not reported’. Some studies may describe a subset of the larger 
cohort as receiving both the index test and reference standard and the entire cohort separately – in 
this instance please only report the age of participants who received both tests. 
3d. Number of participants 
Please write in the box provided the number of participants and/or the number of samples included 
in the study. Some studies may describe a subset of the larger cohort who received both the index 
test and reference standard and the entire cohort separately – in this instance please report only the 
number of participants who received both tests (i.e. the subset of participants who received both 
HAND and STAND). You may also state that the study consisted of a large cohort with a subset within 
that cohort in the space provided for ‘number of samples’. 
3e. Proportion or number of participants by gender 
Please write in the box provided the proportion/percentage or number of participants per sex of 
those who received both tests (i.e. those that received both HAND and STAND). For example; 50% of 
participants were female or 590 females were in the study. This information can usually be found in 
the results section but if the sex of participants was not specified please tick the box ‘Sex not 
specified’. 
 






For questions 4 and 5, drawing a flow diagram of the study may be helpful. Flow diagrams of 
participant selection, flow and timing illustrate the number of participants who were eligible for the 
study, how many were actually recruited, the proportion of which received the index test as well as 
the proportion of which received the reference standard etc. In addition, the number of true and 
false positives and true and false negatives are also displayed. If necessary please draw a flow 
diagram for the primary study in the space provided on page 6 of the data extraction form. 
 
































(4) PARTICIPANT SELECTION 
These questions have been designed to help assess the risks of bias in the study. 
4a. Please cite here the selection criteria 
Please list the inclusion and exclusion criteria which were applied when recruiting study participants 
in the spaces provided. Inclusion criteria might also include the characteristics of included 
participants. For example “all children attending primary schools in the area were eligible for 
inclusion”. If no criteria were reported, please tick ‘Not reported’ and if the criteria were unclear 
please tick “Unclear” and explain your answer. 
4b. Stage of disease 
Participants recruited into the study may be with or without symptoms. Please indicate the disease 
stage of participants at the time of enrolment by ticking the appropriate box. If the study does not 
clearly report the clinical status of participants, please tick the box marked ‘unclear’ and comment in 
the space provided.  
4c. What was the study design? 
Please indicate the design of the study by ticking one of the choices provided. 
We will not include case-control studies which include healthy controls, alternative diagnosis 
controls or controls from non-endemic areas. Research has shown that these types of studies have a 
tendency to overestimate accuracy measures. Healthy controls are those who have been confirmed 
as being disease-free, alternative diagnosis controls are controls that have similar symptoms to 
those of the disease under study but do not have the condition of interest and controls from non-
endemic areas are those from areas in which the condition of interest is not highly prevalent. If the 
study design is not reported or is unclear please tick the appropriate box and if necessary add a 
comment. 
4d. Was a case-control design avoided? 
 Yes: If the authors report using any study design apart from a case-control one. 
 No: If the authors report using a case-control study design. 
 Unclear: If the authors do not explicitly report the study design used. 
4e. Was a consecutive or random sample of participants enrolled? 
 Yes: If the authors report random sampling or consecutive enrolment of participants. 
 No: If participants were selected, for example based on previous (reference or index) test 
results. 
 Unclear: There appears to be no problem, but the authors do not explicitly state that 
participants were enrolled randomly or consecutively. 




4f. Did the study avoid inappropriate exclusions? 
 Yes: If no participants were excluded after inclusion/enrolment.  
 No: If, for example, participants with mild disease severity were excluded, because they are 
more difficult to detect. 
 Unclear: If not reported or insufficient information given to make a decision. 
4g.   Could the selection of participants have introduced bias? 
 Low: If both questions 4d and 4e were answered ‘yes’  or if at most one was answered 
‘unclear’. 
 High: If one or more of questions 4d and 4e were answered ‘no’. 
 Unclear: Any other combination of answers, for example if both questions 4d and 4e were 
answered ‘unclear’. 
4h. Is there a concern that the included participants do not match the review question?  
 Low concern: If study participants reside within RHD endemic areas as they will include 
those at risk of infection, those who are infected but asymptomatic as well as those who are 
infected and have symptoms. 
 High concern: If study participants don't reside in endemic areas. For example; tourists, 
healthy controls or controls with alternative diagnoses. 
 Unclear: If there is insufficient information to make a decision. 
(5) PARTICIPANT FLOW AND TIMING 
5a. Was there an appropriate interval between index test and reference standard?  
 Yes:  If the participants were examined using both the reference standard and index test at 
the same time or within a two week time period. 
 No: If the time period between index and reference standard was more than two weeks. 
 Unclear:  If there is no or insufficient information on time period. 
5b. Did all participants receive a reference standard? (Focus on participants included in the 2*2 
table)  
 Yes: If the whole study sample or a random selection of the sample or a selection of the 
sample with consecutive series receive verification using the reference standard. 
 No: If a part of the study sample that is non-randomly or non-consecutively selected 
receives verification using the reference standard. 
 Unclear: If there is no or insufficient information to ascertain whether the whole sample or a 
random selection of the sample received verification using the reference standard. 




5c. Did participants receive the same reference standard?  
 Yes: If study participants are tested with the same reference standard (2D, continuous-wave, 
and colour Doppler echocardiography) regardless of index test result. 
 No: If 2D, continuous-wave, and colour Doppler echocardiography is used with different 
techniques depending on the results of the index test. 
 Unclear: If there is no or insufficient information on the reference standard used. 
5d. Were all participants included in the analysis?  
 Yes: If all the participants that were included in the study, were also included in the analysis. 
 No: If some participants / results are missing in the analysis. 
 Unclear: If there is no or insufficient information to make a decision. 
5e. Could the conduct or interpretation of participant flow & timing have introduced bias? 
 Low: If all questions were answered ‘yes’ or at least three were answered ‘yes’ and the other 
‘unclear’. 
 High: If two or more of questions 5a - 5d were answered ‘no’. 
 Unclear: Any other combination of answers. For example if all questions were answered 
‘unclear’ or if three were ‘unclear’ and one was ‘yes’. 
(6) INDEX TEST 
6a. Please state the name and specifications of the index test under evaluation in the study. 
Please state the name/label of the index test as well as any additional specifications. The label is the 
brand name of the test or the manufacturer who made the device. Additional specifications might 
include the type of transducer/probe attached to the device. If the brand name or label is not 
reported please tick the box ‘Not reported’. Please also describe the person(s) performing and 
interpreting the test as well as the time at which interpretation occurred. In some instances the 
person(s) performing the index test might be different from the person(s) interpreting the test 
results – please describe both. Please also describe the time at which the index test results were 
interpreted, for example on-site at the time of screening/evaluation or later/offline.  
6b. Was a pre-specified set of diagnostic criteria or protocol used?  
 Yes: If a pre-specified modified diagnostic protocol or set of diagnostic criteria for HAND was 
used. 
 No: If no pre-specified set of diagnostic criteria or diagnostic protocol was used or if criteria 
were not modified to suit the capabilities of HAND. 
 Unclear: If there is insufficient information to make a judgment. 
 Not reported: If there is no information reported on this item. 




6c. Was the HAND interpreter trained to use the diagnostic protocol? 
 Yes: If the person who conducted the echocardiographic screening using the handheld 
device was trained on how to interpret results using the pre-specified diagnostic protocol or 
if the person interpreting the HAND results is described as an expert/experienced 
reviewer/imager/reader. For example this might include any of the following; paediatric 
cardiologists, paediatric cardiology fellows, echocardiography imagers/technicians & 
sonographers. 
 No: If the person who conducted echocardiographic screening using the handheld device 
does not have any prior experience or expertise in interpreting echocardiographic images 
and was not given any training with regards to interpreting results using a pre-specified 
diagnostic protocol.  
 Unclear: If there is insufficient information to make a judgment. 
 Not reported: If there is no information reported on this item. 
6d. What was the initial level of expertise of the HAND interpreter? 
Please state the HAND interpreter’s initial level of clinical expertise. For example were they a 
clinician, nurse or community health worker etc. If not reported please tick the appropriate box and 
if necessary comment in the space provided. 
6e. Was quality control done? 
To ensure reliability or good quality of results a sub-set of the sample population may be cross-
checked by a second person or an expert in echocardiographic imaging. Please indicate if this was 
done in the study. If the information is insufficient or if the information given is unclear please tick 
the box ‘unclear’. If not reported, tick the box ‘Not reported’ and if necessary, comment in the box 
provided. 
6f. Were the index test results interpreted without knowledge of the results of the reference 
standard? 
 Yes: If results of the index test are interpreted without knowledge of reference test results 
or if the index test is performed prior to administering the reference standard. 
 No: If results of the index test are interpreted with knowledge of the reference standard test 
results. 
 Unclear: If there is insufficient information on when the index and reference tests were 
interpreted. 
 Not reported: If no information was reported with regards to the timing and interpretation 
of tests. 
 




6g. If a threshold was used, was it pre-specified? 
 Yes: If the authors report the use of a primary, pre-specified, cut-off value or threshold. A 
pre-specified threshold also includes statements such as “the test was scored according to 
manufacturer’s instructions”. 
 No: If multiple cut-off values were tested and the best one chosen afterwards. 
 Unclear: If only one cut-off value was used, but this was not explicitly reported in the 
methods section. 
 Not reported: If no information was reported on this item. 
6h. Could the conduct or interpretation of the index test have introduced bias? 
 Low: If questions 6b – 6g were all answered ‘yes’. 
 High: If one or more of questions 6b – 6g were answered ‘no’. 
 Unclear: Any other combination of answers. For example if one or more questions were 
answered ‘unclear’. 
(7) REFERENCE TEST 
 
The reference test for RHD that this review will evaluate is 2D continuous-wave, and colour Doppler 
echocardiography with results interpreted in accordance with the 2012 WHF criteria. 
7a. Please indicate the reference test applied in the study  
For RHD, if the reference test used was not 2D, continuous-wave, and colour Doppler 
echocardiography tick ‘other’ and EXCLUDE the paper. 
Please state the name/label of the reference standard machine as well as any additional 
specifications. The label is the brand name of the test or the manufacturer who made the device. 
Additional specifications might include the type of transducer/probe attached to the machine. If the 
brand name or label is not reported please tick the box ‘Not reported’. Please also describe the 
person(s) performing and interpreting the test as well as the time at which interpretation occurred. 
In some instances the person(s) performing the index test might be different from the person(s) 
interpreting the test results – please describe both. Please also describe the time at which the index 
test results were interpreted, for example on-site at the time of screening/evaluation or 
later/offline.  
7b. Number of reference test images examined per participant 
Please state the number of images recorded and examined per participant using 2D, continuous-
wave, and colour Doppler echocardiography. If a different number of images were examined per 
participant or if the information is insufficient please tick the box marked ‘unclear’. If no information 
is reported please tick the box ‘Not reported’.  




The following questions (7c-7f) are part of the QUADAS-2 tool and will be used to assess the risk of 
bias in how the reference test was conducted. 
 
7c. Was quality control done? 
To ensure reliability the test results for a subset of the sample population may be cross checked by a 
second person or an expert in echocardiographic imaging. Please indicate if this was done in the 
study. This might include all suspected cases (definite or borderline) on STAND being independently 
reviewed by a second reader with conflicts adjudicated by a third reader if necessary. If information 
is insufficient to make a judgment please tick the box ‘unclear’. If no information is reported please 
tick the box ‘Not reported’ and if necessary, comment in the box provided. 
7d. Is the reference standard likely to correctly classify the target condition?    
 Yes:  If measures to increase sensitivity are used e.g. multiple angles/images examined per 
patient and machine settings optimised.  
 No: If for example only ill children are sampled for testing using the reference standard. 
 Unclear: If there is insufficient information on the reference standard used or echo imaging 
technique used to make a judgment. 
7e. Were the reference standard results interpreted without knowledge of the results of the index 
test? 
 Yes: If results of the reference standard are interpreted without knowledge of index test 
results in cases when the reference test was used before the index test. 
 No: If results of the reference test are interpreted with knowledge of the index test results in 
cases when the index test is performed before the reference test.  
 Unclear: If there is insufficient information on when the index and reference tests were 
interpreted. 
 Not reported: If no information was reported on this item. 
7f. Could the conduct or interpretation of the reference standard have introduced bias? 
 Low: If questions 7c – 7e were all answered ‘yes’. 
 High: If one or more of questions 7c – 7e were answered ‘no’. 
 Unclear: Any other combination of answers. 
(8) TEST RESULTS 
8a. Prevalence of disease based on STAND results  
[For those who received the reference test regardless of whether or not they also received the index 
test] 




Please state the reported prevalence estimates for rheumatic heart disease based on the reference 
standard test results. Report these measures in terms of the mean, 95% confidence interval and 
range. Please report the results for all participants in the study who were screened for RHD using 
standard echocardiography. In some instances this indicates the larger cohort of participants who 
were all screened for RHD using STAND but of which some did not receive the index test as well. This 
is fine as long as all participants screened received the same reference standard test. If this 
information is not given or cannot be extracted from the results provided please tick the box ‘Not 
reported’ and add a comment in the space provided if necessary. 
8b. Severity of disease  
[Only for those who received both the index and reference test] 
Please indicate the range of disease severity for the participants included in the study who received 
both the index test (HAND) and the reference test (STAND) according to assessment by standard 
echocardiography. For example state the number or proportion of participants who were diagnosed 
as having definite RHD, borderline RHD or normal echocardiographic findings according to 
assessment by standard echocardiography. If no information is given please tick the box ‘Not 
reported’. 
8c. Missing data 
Please indicate if there were missing, uninterpretable or unavailable results for both the reference 
standard and index tests by ticking the appropriate boxes.  These may or may not be reported by the 
authors. Please explain your answers in the comment boxes provided citing the number of missing / 
uninterpretable / unavailable test results. 
 
To understand the following section better please refer to the paper by van Stralen K et al (2009). 
‘Diagnostic Methods I: sensitivity, specificity, and other measures of accuracy’. Kidney International, 
75; 1257-1263. 
 
8d. Accuracy results 
Please ONLY report accuracy results for handheld echocardiography (HAND). Do not report results 
for auscultation or any other tests. 
 Please extract the required data into the 2 by 2 table by listing the results in the spaces 
provided using the following format: True Positives (TP), True Negatives (TN), False Positives 
(FP), False Negatives (FN), Sensitivity (Sens), Specificity (Spec), Positive Predictive Value 
(PPV) and Negative Predictive Value (NPV). Please also extract 95% confidence intervals for 
measures of sensitivity, specificity, PPV and NPV if and when reported by study authors.  




 In the first column (Test) please specify whether the results refer to any RHD (definite or 
borderline) or to definite RHD only. Please also further specify, where applicable, whether 
the results are pooled/combined (i.e. for all experts/non-experts/nurses etc.) or if the results 
are for different individuals (i.e. Nurse A or Nurse B). Please report all permutations thereof, 
for instance report the results for nurse A, then for Nurse B and lastly both of their results 
combined. 
 Please specify the threshold or cut-off value in terms of mitral regurgitation (MR) &/or aortic 
regurgitation (AR) in the second column (Threshold). If multiple different thresholds were 
used, please report the results for each threshold separately (i.e. each one on a different 
row). 
General comments 
At the end of the data extraction form a comment box has been provided for general comments 
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APPENDIX 5: PRISMA-DTA 2018 CHECKLIST 
 
 
Section and Topic  
Item 
No. 
Description Page (Part)  
Title   
Title  1 Identify the report as a systematic review (meta-analysis) of DTA studies.  5 (Part C) 
Abstract  
Abstract  2 
Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
1-2 (Part C) 
Introduction  
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 (Part C) 
Clinical role of index test D1 
State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the 
rationale for minimally acceptable test accuracy (or minimum difference in accuracy for a comparative design). 
4 (Part C) 
Objectives  4 Provide an explicit statement of questions being addressed in terms of participants, index test, and target conditions.  5-7 (Part A) 
Methods  
Protocol and registration  5 Indicate where the review protocol can be accessed (eg, web address) and provide trial registration number if available.  4 (Part C) 
Eligibility criteria  6 
Specify study characteristics (participants, setting, index test, reference standards, target conditions, and study design) and 
report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility and providing rationale.  
7 (Part A) 
Information sources  7 
Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and the date last searched.  
8 (Part A) 
Search  8 
Present full search strategies for all electronic databases and other sources searched, including any limits used so that they can 
be repeated.  
9 (Part A) 
Study selection  9 
State the process for selecting studies (e.g., screening, eligibility, whether included in systematic review, and, if applicable, 
included in the meta-analysis).  
10 (Part A) 
Data collection process  10 
Describe methods of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
10-11 (Part A) 
Definitions for data extraction 11 
Provide definitions used in data extraction and classifications of target conditions, index tests, reference standards, and other 
characteristics (eg, study design, clinical setting).  
See background 
document (Part D) 
Risk of bias and applicability 12 
Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review 
question. 
11-12 (Part A) 
 




Diagnostic accuracy measures  13 
State the principal diagnostic accuracy measures reported (eg, sensitivity, specificity) and state the unit of assessment (eg, per 
patient vs per lesion). 
7 (Part A) 
Synthesis of results 14 
Describe the methods of handling the data, combining the results of the studies and describing the variability between studies. 
This could include, but is not limited to (1) handling of multiple definitions of the target condition, (2) handling of multiple 
thresholds of test positivity, (3) handling multiple index test readers, (4) handling of indeterminate test results, (5) grouping 
and comparing tests, and (6) handling of different reference standards. 
13-14 (Part A) 
Meta-analysis D2 Report statistical methods used for meta-analyses if performed. 20 (Part C) 
Additional analyses  16 
Describe the methods of the additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were prespecified.  
20-21 (Part C) 
Results  
Study selection  17 
Provide the numbers of studies screened, assessed for eligibility, included in the review, and included in the meta-analysis if 
applicable, with reasons for exclusions at each stage, ideally with a flow diagram.  
4-5 (Part C) 
Study characteristics  18 
For each included study, provide citations and present key characteristics including (1) participant characteristics (presentation, 
prior testing), (2) clinical setting, (3) study design, (4) target condition definition, (5) index test, (6) reference standard, (7) 
sample size, and (8) funding sources. 
6-8 (Part C) 
Risk of bias and applicability 19 Present evaluation of risk of bias and concerns regarding applicability for each study. 9-11 (Part C) 
Results of individual studies  20 
For each analysis in each study (eg, unique combination of index test, reference standard, and positivity threshold), report 2 × 2 
data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest plot or a receiver 
operating characteristic curve. 
14, 16 & 18 (Part C) 
Synthesis of results  21 Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals.  13, 15 & 17 (Part C) 
Additional analysis  23 
Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression, analysis of index test, failure 
rates, proportion of inconclusive results, and adverse events).  
19-21 (Part C) 
Discussion  
Summary 24 Summarize the main findings including the strength of evidence.  21-25 (Part C) 
Limitations  25 
Discuss limitations from included studies (eg, risk of bias and concerns regarding applicability) and from the review process (eg, 
incomplete retrieval of identified research).  
25 (Part C) 
Conclusions  26 
Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and 
clinical practice (eg, the intended use and clinical role of the index test). 
26-28 (Part C) 
Funding  
Funding  27 For the systematic review, describe the sources of funding and other support and the role of the funders. 29 (Part C) 
Abbreviations: FN, false negative; FP, false positive; TN, true negative; TP, true positive 
From: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA 
Statement. JAMA 319(4): 388 - 396. doi: 10.1001/jama.2017.19163. 




APPENDIX 6: SUPPLEMENTARY TABLES AND FIGURES 
 
Appendix 6(a) pooled prevalence estimates 
 




















*All pooled prevalence estimates were generated using STATA software.  




APPENDIX 7: TECHNICAL APPENDICES  
 
Appendix 7(a) statistical formulae and calculations 
 
Supposing the means are given by M1, M2, M3 and M4 and the SD's are S1, S2, S3 and S4. 
Let N1, N2, N3 and N4 represent the respective numbers of observations for each groups.  
 
Formula for and calculation of the pooled mean: 
Pooled mean = (N1*M1 + N2*M2 + N3*M3 + N4*M4) / (N1 + N2 + N3 + N4) 
= (1217*9.6 + 397*13.9 + 956*11.1 + 1317*10.8 + 1420*10.8) / (1217 + 397 + 956 + 1317 + 
1420) 
= 10.8 years 
 
Formula for and calculation of the pooled SD: 
Pooled SD = {(N1-1)*S1 + (N2-1)*S2 + (N3-1)*S3 + (N4-1)*S4} / (N1 + N2 + N3 + N4) 
= {(1217-1)*0.5 + (397-1)*2.6 + (956-1)*2.5 + (1317-1)*2.6 + (1420-1)*2.6} / 
(1217+397+956+1317+1420) 
= 2.1 
